

PI3K and cancer: lessons, challenges and opportunities

Nature Reviews Drug Discovery

13, 140-156

DOI: [10.1038/nrd4204](https://doi.org/10.1038/nrd4204)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines. <i>PLoS ONE</i> , 2014, 9, e105792.	1.1	23
2	Immunohistochemical Analysis of the Mechanistic Target of Rapamycin and Hypoxia Signalling Pathways in Basal Cell Carcinoma and Trichoepithelioma. <i>PLoS ONE</i> , 2014, 9, e106427.	1.1	17
3	Somatic Mosaicism in the Human Genome. <i>Genes</i> , 2014, 5, 1064-1094.	1.0	122
4	Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells. <i>Blood Cancer Journal</i> , 2014, 4, e234-e234.	2.8	11
5	Dual loss of PI3K α and PI3K β signaling leads to an age-dependent cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 77, 155-159.	0.9	9
6	Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. <i>Cell Death and Disease</i> , 2014, 5, e1223-e1223.	2.7	57
7	The HER2 Signaling Network in Breast Cancer "Like a Spider in its Web. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2014, 19, 253-270.	1.0	65
8	Crimean-Congo Hemorrhagic Fever Virus Entry into Host Cells Occurs through the Multivesicular Body and Requires ESCRT Regulators. <i>PLoS Pathogens</i> , 2014, 10, e1004390.	2.1	49
9	Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. <i>Molecular and Cellular Oncology</i> , 2014, 1, e963447.	0.3	9
10	Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. <i>Frontiers in Oncology</i> , 2014, 4, 108.	1.3	92
11	Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities. <i>International Journal of Molecular Sciences</i> , 2014, 15, 18856-18891.	1.8	63
12	Idelalisib " A PI3K δ Inhibitor for B-Cell Cancers. <i>New England Journal of Medicine</i> , 2014, 370, 1061-1062.	13.9	86
13	Recent Advances in the Pathogenesis and Treatment of Chronic Lymphocytic Leukemia. <i>Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki</i> , 2014, 35, 105-120.	0.2	2
14	DNA "PKcs "SIN1 complexation mediates low-dose X-ray irradiation (LDI)-induced Akt activation and osteoblast differentiation. <i>Biochemical and Biophysical Research Communications</i> , 2014, 453, 362-367.	1.0	17
15	Targeting survival and cell trafficking in multiple myeloma and Waldenström macroglobulinemia using pan-PI3K inhibitor, buparlisib. <i>American Journal of Hematology</i> , 2014, 89, 1030-1036.	2.0	14
16	Posttranslational regulation of Akt in human cancer. <i>Cell and Bioscience</i> , 2014, 4, 59.	2.1	111
17	Uncovering the PI3Ksome: Phosphoinositide 3-Kinases and Counteracting PTEN Form a Signaling Complex with Intrinsic Regulatory Properties. <i>Molecular and Cellular Biology</i> , 2014, 34, 3356-3358.	1.1	2
18	Clinical value of isoform-specific detection and targeting of AKT1, AKT2 and AKT3 in breast cancer. <i>Breast Cancer Management</i> , 2014, 3, 409-421.	0.2	3

#	ARTICLE	IF	CITATIONS
19	Bruton's tyrosine kinase inhibitors. <i>Current Opinion in Oncology</i> , 2014, 26, 463-468.	1.1	9
20	Editorial. <i>British Journal of Pharmacology</i> , 2014, 171, 5459-5461.	2.7	1
21	PI3K γ Inhibition Hits a Sensitive Spot in B Cell Malignancies. <i>Cancer Cell</i> , 2014, 25, 269-271.	7.7	34
22	Rational combination of dual PI3K/mTOR blockade and Bcl-2/xL inhibition in AML. <i>Physiological Genomics</i> , 2014, 46, 448-456.	1.0	26
23	Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. <i>Gynecologic Oncology</i> , 2014, 135, 312-317.	0.6	33
24	Idelalisib β targeting PI3K δ in patients with B-cell malignancies. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 184-186.	12.5	46
25	Signaling pathway cooperation in TGF- β -induced epithelial \rightarrow mesenchymal transition. <i>Current Opinion in Cell Biology</i> , 2014, 31, 56-66.	2.6	314
26	Phosphatidylinositol 3 β -Phosphate Mimics Based on a Sulfoquinovose Scaffold: Synthesis and Evaluation as Protein Kinase B Inhibitors. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 5962-5967.	1.2	7
27	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. <i>Genes and Diseases</i> , 2014, 1, 75-86.	1.5	78
28	The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 973-978.	1.0	27
29	Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3K δ/γ inhibitors for the treatment of PTEN-deficient tumours. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3928-3935.	1.0	18
30	GDC-0980-induced apoptosis is enhanced by autophagy inhibition in human pancreatic cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 453, 533-538.	1.0	19
31	Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. <i>Journal of Molecular Medicine</i> , 2014, 92, 709-722.	1.7	75
32	The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 25-33.	1.4	167
33	PDGF receptor signaling networks in normal and cancer cells. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 273-283.	3.2	201
34	Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1035-1048.	1.5	18
35	Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. <i>Trends in Biochemical Sciences</i> , 2014, 39, 465-474.	3.7	134
36	Inactivation of PI(3)K p110 β breaks regulatory T-cell-mediated immune tolerance to cancer. <i>Nature</i> , 2014, 510, 407-411.	13.7	450

#	ARTICLE	IF	CITATIONS
37	Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. <i>BMC Cancer</i> , 2015, 15, 894.	1.1	27
38	TGF β 2 regulates the proliferation of lung adenocarcinoma cells by inhibiting PIK3R3 expression. <i>Molecular Carcinogenesis</i> , 2015, 54, E162-71.	1.3	11
39	Raf β interactome in tuning the complexity and diversity of Raf function. <i>FEBS Journal</i> , 2015, 282, 32-53.	2.2	17
40	IDEA: Integrated Drug Expression Analysis—Integration of Gene Expression and Clinical Data for the Identification of Therapeutic Candidates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 415-425.	1.3	5
41	Synergistic induction of cell death in haematological malignancies by combined phosphoinositide β kinase and β bromodomain inhibition. <i>British Journal of Haematology</i> , 2015, 170, 275-278.	1.2	14
43	Different inhibition of G1 β -stimulated class IB phosphoinositide 3-kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as a G1 β -dependent regulator of PI3K β enzymatic activity. <i>Biochemical Journal</i> , 2015, 469, 59-69.	1.7	18
44	Probing the dynamic regulation of peripheral membrane proteins using hydrogen deuterium exchange—MS (HDX—MS). <i>Biochemical Society Transactions</i> , 2015, 43, 773-786.	1.6	56
45	IP3 3-kinase B controls hematopoietic stem cell homeostasis and prevents lethal hematopoietic failure in mice. <i>Blood</i> , 2015, 125, 2786-2797.	0.6	27
46	NF- β and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity. <i>Blood</i> , 2015, 126, 1324-1335.	0.6	23
47	Phosphoinositide 3-kinase/Akt pathway is involved in pingyangmycin-induced growth inhibition, apoptosis and reduction of invasive potential in EOMA mouse hemangioendothelioma cells. <i>Molecular Medicine Reports</i> , 2015, 12, 8275-8281.	1.1	9
48	Highly-accurate metabolomic detection of early-stage ovarian cancer. <i>Scientific Reports</i> , 2015, 5, 16351.	1.6	65
49	The pan-class I phosphatidylinositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. <i>Scientific Reports</i> , 2015, 5, 18137.	1.6	28
50	Chorein Sensitive Dopamine Release from Pheochromocytoma (PC12) Cells. <i>NeuroSignals</i> , 2015, 23, 1-10.	0.5	15
51	Endogenous BDNF augments NMDA receptor phosphorylation in the spinal cord via PLC β , PKC, and PI3K/Akt pathways during colitis. <i>Journal of Neuroinflammation</i> , 2015, 12, 151.	3.1	42
52	Current management of mTOR inhibitor-associated stomatitis. <i>Breast Cancer Management</i> , 2015, 4, 255-264.	0.2	0
53	Efficacy of phosphatidylinositol β kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. <i>International Journal of Cancer</i> , 2015, 137, 2234-2242.	2.3	39
54	RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma. <i>Oncotarget</i> , 2015, 6, 28120-28131.	0.8	26
55	MUC16-mediated activation of mTOR and c-MYC reprograms pancreatic cancer metabolism. <i>Oncotarget</i> , 2015, 6, 19118-19131.	0.8	61

#	ARTICLE	IF	CITATIONS
56	MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	23
58	PI3K and AKT: Unfaithful Partners in Cancer. <i>International Journal of Molecular Sciences</i> , 2015, 16, 21138-21152.	1.8	208
59	Profiling Invasiveness in Head and Neck Cancer: Recent Contributions of Genomic and Transcriptomic Approaches. <i>Cancers</i> , 2015, 7, 585-597.	1.7	8
60	Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 16, 29-37.	0.9	16
61	Pik3ip1 Modulates Cardiac Hypertrophy by Inhibiting PI3K Pathway. <i>PLoS ONE</i> , 2015, 10, e0122251.	1.1	42
62	Loss of Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) Does Not Affect Proliferation and Survival of Multiple Myeloma Cell Lines. <i>PLoS ONE</i> , 2015, 10, e0122689.	1.1	4
63	Curcumin Induces Apoptosis of Upper Aerodigestive Tract Cancer Cells by Targeting Multiple Pathways. <i>PLoS ONE</i> , 2015, 10, e0124218.	1.1	34
64	BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer. <i>PLoS ONE</i> , 2015, 10, e0133081.	1.1	22
65	Parasporin-2 from a New <i>Bacillus thuringiensis</i> 4R2 Strain Induces Caspases Activation and Apoptosis in Human Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0135106.	1.1	44
66	Activation of the Mammalian Target of Rapamycin in the Rostral Ventromedial Medulla Contributes to the Maintenance of Nerve Injury-Induced Neuropathic Pain in Rat. <i>Neural Plasticity</i> , 2015, 2015, 1-16.	1.0	8
67	MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulation. <i>Oncotarget</i> , 2015, 6, 6359-6372.	0.8	36
68	Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. <i>Oncotarget</i> , 2015, 6, 10102-10115.	0.8	61
69	MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. <i>Oncotarget</i> , 2015, 6, 35202-35217.	0.8	23
70	mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. <i>Oncotarget</i> , 2015, 6, 2088-2100.	0.8	30
71	Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. <i>Molecular and Cellular Therapies</i> , 2015, 3, 2.	0.2	101
72	Deregulation of EGFR/PI3K and activation of PTEN by photodynamic therapy combined with carboplatin in human anaplastic thyroid cancer cells and xenograft tumors in nude mice. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2015, 148, 118-127.	1.7	15
73	Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. <i>Neuro-Oncology</i> , 2015, 17, 1275-1283.	0.6	61
74	CC-223, a Potent and Selective Inhibitor of mTOR Kinase: <i>In Vitro</i> and <i>In Vivo</i> Characterization. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1295-1305.	1.9	48

#	ARTICLE	IF	CITATIONS
75	miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation. Archives of Gynecology and Obstetrics, 2015, 292, 1109-1116.	0.8	41
76	Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo. Tumor Biology, 2015, 36, 5699-5706.	0.8	19
77	Rapamycin can restore the negative regulatory function of transforming growth factor beta 1 in high grade lymphomas. Cytokine, 2015, 73, 219-224.	1.4	8
78	Myosin-X and disease. Experimental Cell Research, 2015, 334, 10-15.	1.2	38
79	Design of selective PI3K α inhibitors starting from a promiscuous pan kinase scaffold. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2679-2685.	1.0	9
80	<i>In Vivo</i> Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K α -AKT Signaling at Endosomes. Cancer Discovery, 2015, 5, 740-751.	7.7	86
81	P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity. Molecular Cancer Therapeutics, 2015, 14, 1095-1106.	1.9	11
82	PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3 β /CTNNB1 signaling pathway. Scientific Reports, 2015, 5, 8997.	1.6	56
83	PI3K at the crossroads of tumor angiogenesis signaling pathways. Molecular and Cellular Oncology, 2015, 2, e975624.	0.3	29
84	Cell cycle status dictates effectiveness of rapamycin. Cell Cycle, 2015, 14, 2556-2557.	1.3	3
85	Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. Visceral Medicine, 2015, 31, 424-432.	0.5	2
86	miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway. International Journal of Molecular Medicine, 2015, 35, 1301-1308.	1.8	68
87	GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines. International Journal of Oncology, 2015, 47, 1143-1159.	1.4	39
88	miRNA-542-3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation. Oncology Reports, 2015, 33, 1215-1220.	1.2	38
89	Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2-mediated glycolysis. Oncology Reports, 2015, 33, 1533-1539.	1.2	43
90	Sp1-CD147 positive feedback loop promotes the invasion ability of ovarian cancer. Oncology Reports, 2015, 34, 67-76.	1.2	17
91	Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clinical Cancer Research, 2015, 21, 1537-1542.	3.2	193
92	Akt-Mediated Phosphorylation of XLF Impairs Non-Homologous End-Joining DNA Repair. Molecular Cell, 2015, 57, 648-661.	4.5	59

#	ARTICLE	IF	CITATIONS
93	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. <i>EMBO Reports</i> , 2015, 16, 280-296.	2.0	200
94	Recent Advances in Cancer Therapeutics. <i>Progress in Medicinal Chemistry</i> , 2015, 54, 1-63.	4.1	32
95	Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 823-834.	1.5	3
96	Structure-Based Lead Optimization and Biological Evaluation of BAX Direct Activators as Novel Potential Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2135-2148.	2.9	41
97	The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 137, 173-179.	0.6	336
98	Ten things you should know about protein kinases: <sc>IUPHAR R</sc>view 14. <i>British Journal of Pharmacology</i> , 2015, 172, 2675-2700.	2.7	270
99	The P2X7 receptor is a key modulator of the PI3K/GSK3 β /VEGF signaling network: evidence in experimental neuroblastoma. <i>Oncogene</i> , 2015, 34, 5240-5251.	2.6	149
100	Molecular Pathways: Targeting <i>NRG1</i> Fusions in Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1989-1994.	3.2	61
101	A long non-coding RNA links calreticulin-mediated immunogenic cell removal to RB1 transcription. <i>Oncogene</i> , 2015, 34, 5046-5054.	2.6	39
102	Mendelian disorders of PI metabolizing enzymes. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 867-881.	1.2	42
103	Synergy in activating class I PI3Ks. <i>Trends in Biochemical Sciences</i> , 2015, 40, 88-100.	3.7	164
104	Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. <i>Archives of Toxicology</i> , 2015, 89, 1401-1438.	1.9	492
105	AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation. <i>Angiogenesis</i> , 2015, 18, 151-162.	3.7	110
106	Targeting the translation machinery in cancer. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 261-278.	21.5	628
107	MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. <i>Cell Death and Disease</i> , 2015, 6, e1593-e1593.	2.7	292
108	Detection and manipulation of phosphoinositides. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 736-745.	1.2	75
109	Poly- β -Glutamic Acid Induces Apoptosis via Reduction of COX-2 Expression in TPA-Induced HT-29 Human Colorectal Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2015, 16, 7577-7586.	1.8	14
110	A Specific A/T Polymorphism in Western Tyrosine Phosphorylation B-Motifs Regulates Helicobacter pylori CagA Epithelial Cell Interactions. <i>PLoS Pathogens</i> , 2015, 11, e1004621.	2.1	83

#	ARTICLE	IF	CITATIONS
111	Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5323-5333.	2.9	29
112	Metabolic dysregulation in monogenic disorders and cancer – finding method in madness. <i>Nature Reviews Cancer</i> , 2015, 15, 440-448.	12.8	89
113	Modification of N-(6-(2-methoxy-3-(4-fluorophenylsulfonamido)pyridin-5-yl)-[1,2,4]triazolo[1,5-a]Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Bioorganic and Medicinal Chemistry, 2015, 23, 5662-5671.	1.4	12
114	Differential profile of PIP4K2A expression in hematological malignancies. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 228-235.	0.6	6
115	Radiotherapy in the Era of Precision Medicine. <i>Seminars in Radiation Oncology</i> , 2015, 25, 227-236.	1.0	29
116	Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?. <i>Advances in Biological Regulation</i> , 2015, 59, 19-35.	1.4	65
117	Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 31-40.	1.1	29
118	Genetics and Pharmacology of Longevity. <i>Advances in Genetics</i> , 2015, 90, 1-101.	0.8	35
119	Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. <i>Gynecologic Oncology</i> , 2015, 138, 323-331.	0.6	19
120	Inhibition of the autocrine IL-6/JAK2/STAT3/calprotectin axis as targeted therapy for HR ⁺ /HER2 ⁺ breast cancers. <i>Genes and Development</i> , 2015, 29, 1631-1648.	2.7	94
121	INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency. <i>Cancer Discovery</i> , 2015, 5, 697-700.	7.7	17
122	Disentangling the Complexity of HGF Signaling by Combining Qualitative and Quantitative Modeling. <i>PLoS Computational Biology</i> , 2015, 11, e1004192.	1.5	15
123	Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5599-5608.	2.9	60
124	PI3K inhibitors in inflammation, autoimmunity and cancer. <i>Current Opinion in Pharmacology</i> , 2015, 23, 82-91.	1.7	258
125	Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration. <i>Journal of Controlled Release</i> , 2015, 213, 112-119.	4.8	21
126	Regulation of mTORC1 by PI3K signaling. <i>Trends in Cell Biology</i> , 2015, 25, 545-555.	3.6	636
127	Current and future molecular diagnostics in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1061-1074.	1.5	14
128	Inhalational Anesthetic Agents and Their Effects on Cancer Cell Biology. <i>Current Anesthesiology Reports</i> , 2015, 5, 268-277.	0.9	2

#	ARTICLE	IF	CITATIONS
129	The New Era of Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2015, 128, 1-68.	1.9	41
130	Phosphoinositide dynamics in the postsynaptic membrane compartment: Mechanisms and experimental approach. <i>European Journal of Cell Biology</i> , 2015, 94, 401-414.	1.6	11
131	Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv171-djv171.	3.0	78
132	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8638-8643.	3.3	174
133	Conditional disruption of rictor demonstrates a direct requirement for mTORC2 in skin tumor development and continued growth of established tumors. <i>Carcinogenesis</i> , 2015, 36, 487-497.	1.3	24
134	Substrate recognition and function of the R2TP complex in response to cellular stress. <i>Frontiers in Genetics</i> , 2015, 6, 69.	1.1	31
135	Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	91
136	The PI3K/AKT/mTOR interactive pathway. <i>Molecular BioSystems</i> , 2015, 11, 1946-1954.	2.9	379
137	Nuclear PI3K signaling in cell growth and tumorigenesis. <i>Frontiers in Cell and Developmental Biology</i> , 2015, 3, 24.	1.8	97
138	Levels of sirolimus in saliva and blood following oral topical sustained-release varnish delivery system application. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 969-974.	1.1	8
139	Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015, 20, 535-550.	2.2	28
140	The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation. <i>International Journal of Hematology</i> , 2015, 102, 12-24.	0.7	10
141	Development of in vitro PIK3C3/VPS34 complex protein assay for autophagy-specific inhibitor screening. <i>Analytical Biochemistry</i> , 2015, 480, 21-27.	1.1	6
142	Process Development and Scale-Up of a Benzoxazepine-Containing Kinase Inhibitor. <i>Organic Process Research and Development</i> , 2015, 19, 721-734.	1.3	19
143	Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 99, 36-50.	2.6	25
144	FDA-approved small-molecule kinase inhibitors. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 422-439.	4.0	794
145	Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond. <i>Medicinal Research Reviews</i> , 2015, 35, 720-752.	5.0	22
146	The PI3K/AKT Pathway and Renal Cell Carcinoma. <i>Journal of Genetics and Genomics</i> , 2015, 42, 343-353.	1.7	267

#	ARTICLE	IF	CITATIONS
147	Human ACAP2 is a homolog of <i>C. elegans</i> CNT-1 that promotes apoptosis in cancer cells. <i>Cell Cycle</i> , 2015, 14, 1771-1778.	1.3	8
148	Quinazoline derivatives as anticancer drugs: a patent review (2011 – present). <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 789-804.	2.4	93
149	Inhibition of PI3K ^{Î²} Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 48-58.	1.9	75
150	Adipose tissue dysfunction and its effects on tumor metabolism. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2015, 21, 17-41.	0.3	31
151	The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. <i>Leukemia</i> , 2015, 29, 1811-1822.	3.3	151
152	The biology behind PI3K inhibition in chronic lymphocytic leukaemia. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 25-36.	1.1	13
153	Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies. <i>Drug Discovery Today</i> , 2015, 20, 988-994.	3.2	43
154	The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 931-940.	1.9	45
155	Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 3160-3169.	3.2	51
156	Disabling mitochondrial reprogramming in cancer. <i>Pharmacological Research</i> , 2015, 102, 42-45.	3.1	3
157	Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia. <i>European Journal of Cancer</i> , 2015, 51, 2076-2085.	1.3	21
158	Allosteric small-molecule kinase inhibitors. , 2015, 156, 59-68.		166
159	Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 822-846.	4.0	242
160	Activated phosphoinositide 3-kinase ^{Î³} syndrome in a patient with a former diagnosis of common variable immune deficiency, bronchiectasis, and lymphoproliferative disease. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 452-454.	0.5	15
161	Novel drug therapies in myeloid leukemia: a patent review. <i>Pharmaceutical Patent Analyst</i> , 2015, 4, 187-205.	0.4	15
162	Markers in Colorectal Cancer and Clinical Trials Based Upon Them. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 317-325.	1.0	0
163	Oncogenic PI3K ^{Î±} promotes multipotency in breast epithelial cells. <i>Science Signaling</i> , 2015, 8, pe3.	1.6	4
164	Pan-cancer analysis of TCGA data reveals notable signaling pathways. <i>BMC Cancer</i> , 2015, 15, 516.	1.1	33

#	ARTICLE	IF	CITATIONS
165	PIPPing on AKT1: How Many Phosphatases Does It Take to Turn off PI3K?. <i>Cancer Cell</i> , 2015, 28, 143-145.	7.7	9
166	An overview of early investigational therapies for chemoresistant ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1163-1183.	1.9	15
167	The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4136-4142.	1.0	19
168	A Kinase Divided. <i>Cancer Cell</i> , 2015, 28, 145-147.	7.7	2
169	Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma. <i>Journal of Biological Chemistry</i> , 2015, 290, 17495-17504.	1.6	144
170	Breast Cancer Update 2014 – Focus on the Patient and the Tumour. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 170-182.	0.8	9
171	Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment. <i>Translational Oncology</i> , 2015, 8, 185-195.	1.7	145
172	Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3K α and PI3K β for the treatment of cancers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5155-5162.	1.0	29
173	Other Novel Therapies: Biomarkers, microRNAs and microRNA Inhibitors, DNA Methylation, Epigenetics, Immunotherapy and Virotherapy. <i>Frontiers of Hormone Research</i> , 2015, 44, 248-262.	1.0	1
174	Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling. <i>Clinical Cancer Research</i> , 2015, 21, 4508-4513.	3.2	58
175	Amino acid management in cancer. <i>Seminars in Cell and Developmental Biology</i> , 2015, 43, 22-32.	2.3	96
176	MYC and metabolism on the path to cancer. <i>Seminars in Cell and Developmental Biology</i> , 2015, 43, 11-21.	2.3	253
177	Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes. <i>Expert Review of Hematology</i> , 2015, 8, 581-593.	1.0	19
178	Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion. <i>Cell Cycle</i> , 2015, 14, 3242-3247.	1.3	26
179	Cytoskeleton Dynamics in Health and Disease: Role of Molecular Switches and Rheostats. , 2015, , 11-62.		2
180	Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7765-7776.	1.4	19
181	Insulin's InsR signaling drives multipotent progenitor differentiation toward lymphoid lineages. <i>Journal of Experimental Medicine</i> , 2015, 212, 2305-2321.	4.2	17
182	Pretreatment With Erythropoietin Attenuates Intestinal Ischemia Reperfusion Injury by Further Promoting PI3K/Akt Signaling Activation. <i>Transplantation Proceedings</i> , 2015, 47, 1639-1645.	0.3	15

#	ARTICLE	IF	CITATIONS
183	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1319-1327.	0.5	138
184	Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms. <i>Molecular Cancer</i> , 2015, 14, 118.	7.9	25
185	Feedback Suppression of PI3K β Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3K δ . <i>Cancer Cell</i> , 2015, 27, 109-122.	7.7	203
186	Discovery of (<i>R</i>)-8-(1-(3,5-Difluorophenylamino)ethyl)-<i>N</i>-,<i>N</i>-dimethyl-2-morpholino-4-oxo-4<i>H</i>-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3K δ and PI3K β for the Treatment of PTEN-Deficient Cancers. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 943-962.	2.9	73
187	PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. <i>Nature Reviews Cancer</i> , 2015, 15, 7-24.	12.8	1,083
188	Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. <i>Cancer Letters</i> , 2015, 356, 819-827.	3.2	75
189	Anticancer/Antiviral Agent Akt Inhibitor-IV Massively Accumulates in Mitochondria and Potently Disrupts Cellular Bioenergetics. <i>ACS Chemical Biology</i> , 2015, 10, 570-576.	1.6	11
190	Chemical tools for modulating autophagy. <i>Tetrahedron</i> , 2015, 71, 387-406.	1.0	9
191	Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. <i>Genes and Diseases</i> , 2015, 2, 4-12.	1.5	94
192	Idelalisib for the treatment of B-cell malignancies. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 109-123.	0.5	5
193	Obesity, diabetes and cancer: insight into the relationship from a cohort with growth hormone receptor deficiency. <i>Diabetologia</i> , 2015, 58, 37-42.	2.9	43
194	Recent genetic findings in schizophrenia and their therapeutic relevance. <i>Journal of Psychopharmacology</i> , 2015, 29, 85-96.	2.0	157
195	Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 671-689.	1.2	132
196	How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?. <i>Oncogene</i> , 2015, 34, 3751-3759.	2.6	161
197	Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target. <i>Mini-Reviews in Medicinal Chemistry</i> , 2016, 16, 391-403.	1.1	45
198	Regulation of Autophagy by Actin-Associated Signaling Pathways. , 2016, , 105-122.		0
199	Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?. <i>Stem Cell Investigation</i> , 2016, 3, 31-31.	1.3	18
200	PI3K, AKT, and P-AKT levels in thin endometrium. <i>Genetics and Molecular Research</i> , 2016, 15, .	0.3	8

#	ARTICLE	IF	CITATIONS
201	Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. <i>Cancer Management and Research</i> , 2016, 8, 21.	0.9	9
202	The PI3K/Akt Pathway in Tumors of Endocrine Tissues. <i>Frontiers in Endocrinology</i> , 2015, 6, 188.	1.5	104
203	Export of microRNAs: A Bridge between Breast Carcinoma and Their Neighboring Cells. <i>Frontiers in Oncology</i> , 2016, 6, 147.	1.3	20
204	Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3K ^{Î²} Inhibitors. <i>Molecules</i> , 2016, 21, 876.	1.7	19
205	HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B. <i>PLoS Computational Biology</i> , 2016, 12, e1004827.	1.5	27
206	A 2D-QSAR and Grid-Independent Molecular Descriptor (GRIND) Analysis of Quinoline-Type Inhibitors of Akt2: Exploration of the Binding Mode in the Pleckstrin Homology (PH) Domain. <i>PLoS ONE</i> , 2016, 11, e0168806.	1.1	4
207	Tomato FK506 Binding Protein 12KD (FKBP12) Mediates the Interaction between Rapamycin and Target of Rapamycin (TOR). <i>Frontiers in Plant Science</i> , 2016, 7, 1746.	1.7	40
208	KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. <i>Cancers</i> , 2016, 8, 45.	1.7	147
209	The anticancer properties of phytochemical extracts from Salvia plants. <i>Botanics: Targets and Therapy</i> , 2016, , 25.	0.3	3
210	New perspectives in glioblastoma antiangiogenic therapy. <i>Wspolczesna Onkologia</i> , 2016, 2, 109-118.	0.7	21
211	Perfluorooctanoic acid induces human Ishikawa endometrial cancer cell migration and invasion through activation of ERK/mTOR signaling. <i>Oncotarget</i> , 2016, 7, 66558-66568.	0.8	23
212	MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis. <i>Oncotarget</i> , 2016, 7, 37649-37663.	0.8	30
213	Phase Ib trial of the <sc>PI</sc>3<sc>mTOR</sc> inhibitor voxtalisib (<sc>SAR</sc>245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B–cell malignancies. <i>British Journal of Haematology</i> , 2016, 175, 55-65.	1.2	12
214	RES-529. <i>Anti-Cancer Drugs</i> , 2016, 27, 475-487.	0.7	30
215	Targeting childhood, adolescent and young adult non–Hodgkin lymphoma: therapeutic horizons. <i>British Journal of Haematology</i> , 2016, 173, 625-636.	1.2	5
216	Negative regulation of <sc>TLR</sc> signaling in myeloid cells–implications for autoimmune diseases. <i>Immunological Reviews</i> , 2016, 269, 212-227.	2.8	86
217	Activated mutant forms of <sc>PIK</sc>3<sc>CA</sc> cooperate with RasV12 or c–Met to induce liver tumour formation in mice via <sc>AKT</sc>2/<sc>mTORC</sc>1 cascade. <i>Liver International</i> , 2016, 36, 1176-1186.	1.9	26
218	Enhancing the evaluation of <sc>PI</sc>3K inhibitors through 3D–melanoma models. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 317-328.	1.5	12

#	ARTICLE	IF	CITATIONS
219	The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures. <i>Cancer Drug Discovery and Development</i> , 2016, , 109-124.	0.2	0
220	Mutations in genes encoding <scp>PI3KÁAKT</scp> and <scp>MAPK</scp> signaling define anogenital papillary hidradenoma. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 113-119.	1.5	29
221	miR-18a promotes cell proliferation of esophageal squamous cell carcinoma cells by increasing cyclin D1 via regulating PTEN-PI3K-AKT-mTOR signaling axis. <i>Biochemical and Biophysical Research Communications</i> , 2016, 477, 144-149.	1.0	43
222	Idelalisib. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 12-16.	1.0	4
223	Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. <i>Scientific Reports</i> , 2016, 6, 37997.	1.6	31
224	miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. <i>Oncology Reports</i> , 2016, 36, 3552-3558.	1.2	24
225	Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition. <i>Thorax</i> , 2016, 71, 675-676.	2.7	6
226	FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. <i>EMBO Journal</i> , 2016, 35, 2192-2212.	3.5	58
227	<i>PIK3CA</i> mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. <i>Science Translational Medicine</i> , 2016, 8, 369ra175.	5.8	49
228	Clinicopathological significance of caspase-3 and Ki-67 expression in canine mammary gland tumours. <i>Acta Veterinaria Hungarica</i> , 2016, 64, 78-89.	0.2	8
229	Over-expression of DNA-PKcs in renal cell carcinoma regulates mTORC2 activation, HIF-2 α expression and cell proliferation. <i>Scientific Reports</i> , 2016, 6, 29415.	1.6	40
230	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Breast Diseases</i> , 2016, 27, 315-318.	0.0	0
231	Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells. <i>Oncology Reports</i> , 2016, 36, 3643-3650.	1.2	9
232	Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. <i>Thorax</i> , 2016, 71, 701-711.	2.7	153
233	Somatic <i>PIK3CA</i> mutations as a driver of sporadic venous malformations. <i>Science Translational Medicine</i> , 2016, 8, 332ra42.	5.8	147
234	Targeting CK2-driven non-oncogene addiction in B-cell tumors. <i>Oncogene</i> , 2016, 35, 6045-6052.	2.6	24
235	Therapeutic Benefit of Selective Inhibition of p110 α PI3-Kinase in Pancreatic Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 5805-5817.	3.2	35
236	Synthetic sulfoglycolipids targeting the serineÁthreonine protein kinase Akt. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 3396-3405.	1.4	9

#	ARTICLE	IF	CITATIONS
237	Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells. <i>Oncology Letters</i> , 2016, 11, 1161-1166.	0.8	41
238	Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo. <i>Tumor Biology</i> , 2016, 37, 11743-11752.	0.8	16
239	Resveratrol Potentiates Growth Inhibitory Effects of Rapamycin in <i>PTEN</i> -deficient Lipoma Cells by Suppressing p70S6 Kinase Activity. <i>Nutrition and Cancer</i> , 2016, 68, 342-349.	0.9	7
240	FANCI is a negative regulator of Akt activation. <i>Cell Cycle</i> , 2016, 15, 1134-1143.	1.3	32
241	Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs. <i>Cancer Cell</i> , 2016, 29, 429-431.	7.7	23
242	Perifosine and ABT-737 synergistically inhibit lung cancer cells in vitro and in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 1170-1176.	1.0	32
243	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. <i>Physiological Reviews</i> , 2016, 96, 805-829.	13.1	49
244	Hijacking GPCRs by viral pathogens and tumor. <i>Biochemical Pharmacology</i> , 2016, 114, 69-81.	2.0	27
245	Perspectives on targeting the phosphatidylinositol 3-kinase pathway for personalized medicine in endometrial and ovarian cancers. <i>Personalized Medicine Universe</i> , 2016, 5, 3-7.	0.1	0
246	ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 253-265.	1.1	71
247	Idelalisib in the management of lymphoma. <i>Blood</i> , 2016, 128, 331-336.	0.6	120
248	Translation of Targeted Radiation Sensitizers into Clinical Trials. <i>Seminars in Radiation Oncology</i> , 2016, 26, 261-270.	1.0	16
249	Emerging evidence of signalling roles for PI(3,4)P ₂ in Class I and II PI3K-regulated pathways. <i>Biochemical Society Transactions</i> , 2016, 44, 307-314.	1.6	96
250	Targeting Autophagy in Cancer Therapy. <i>Current Cancer Research</i> , 2016, , .	0.2	28
251	Targeting the Mammalian Target of Rapamycin in Lung Cancer. <i>American Journal of the Medical Sciences</i> , 2016, 352, 507-516.	0.4	18
252	Targeting PI3-Kinases in Modulating Autophagy and Anti-cancer Therapy. <i>Current Cancer Research</i> , 2016, , 85-97.	0.2	0
253	A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). <i>Cancer</i> , 2016, 122, 3519-3528.	2.0	58
254	Regulation of PtdIns(3,4,5)P ₃ /Akt signalling by inositol polyphosphate 5-phosphatases. <i>Biochemical Society Transactions</i> , 2016, 44, 240-252.	1.6	53

#	ARTICLE	IF	CITATIONS
255	The Hidden Conundrum of Phosphoinositide Signaling in Cancer. <i>Trends in Cancer</i> , 2016, 2, 378-390.	3.8	32
256	Cancer network activity associated with therapeutic response and synergism. <i>Genome Medicine</i> , 2016, 8, 88.	3.6	7
257	Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway. <i>Tumor Biology</i> , 2016, 37, 14637-14651.	0.8	14
258	Glucose-regulated protein 78 contributes to the proliferation and tumorigenesis of human colorectal carcinoma via AKT and ERK pathways. <i>Oncology Reports</i> , 2016, 36, 2723-2730.	1.2	8
259	Mammalian target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (<sc>MDS</sc>) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German <sc>MDS</sc> Study Group (D&MDS). <i>British Journal of Haematology</i> , 2016, 175, 917-924.	1.2	8
260	Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 1090-1105.	7.7	217
261	Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001057.	0.5	21
262	Better understanding of phosphoinositide 3-kinase (PI3K) pathways in vasculature: Towards precision therapy targeting angiogenesis and tumor blood supply. <i>Biochemistry (Moscow)</i> , 2016, 81, 691-699.	0.7	12
263	Discovery of a Series of 5,11-Dihydro-6<i>H</i>-benzo[<i>e</i>]pyrimido[5,4-<i>b</i>][1,4]diazepin-6-ones as Selective PI3K-Î³ Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 908-912.	1.3	15
264	Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. <i>Cancer Cell</i> , 2016, 30, 257-272.	7.7	158
265	The PI3K pathway in B cell metabolism. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2016, 51, 359-378.	2.3	106
266	Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2553-2562.	1.9	50
267	Genetic variants in <sc>PI</sc>3K<sc>AKT</sc> pathway are associated with severe radiation pneumonitis in lung cancer patients treated with radiation therapy. <i>Cancer Medicine</i> , 2016, 5, 24-32.	1.3	32
268	The FoxO3 gene and cause-specific mortality. <i>Aging Cell</i> , 2016, 15, 617-624.	3.0	48
269	Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer. <i>Recent Results in Cancer Research</i> , 2016, 207, 39-72.	1.8	143
270	Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4408-4413.	1.0	24
271	The interplay between cell signalling and the mevalonate pathway in cancer. <i>Nature Reviews Cancer</i> , 2016, 16, 718-731.	12.8	447
272	The novel PI3K-Î³ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. <i>Leukemia</i> , 2016, 30, 2402-2405.	3.3	13

#	ARTICLE	IF	CITATIONS
273	Amplification of USP13 drives ovarian cancer metabolism. <i>Nature Communications</i> , 2016, 7, 13525.	5.8	99
274	Inhibition of Ral GTPases Using a Stapled Peptide Approach. <i>Journal of Biological Chemistry</i> , 2016, 291, 18310-18325.	1.6	20
275	Addition of the p110 α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. <i>Tumor Biology</i> , 2016, 37, 14831-14839.	0.8	6
276	Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 3803-3815.	0.8	336
277	PKD1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K α Inhibition. <i>Cancer Cell</i> , 2016, 30, 229-242.	7.7	187
278	Pre-clinical risk assessment and therapeutic potential of antitumor lipopeptide α -L-taurin A α ™ in an in vivo and in vitro model. <i>RSC Advances</i> , 2016, 6, 71612-71623.	1.7	20
279	Causes and consequences of nuclear envelope alterations in tumour progression. <i>European Journal of Cell Biology</i> , 2016, 95, 449-464.	1.6	85
280	Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2344-2356.	1.9	61
281	Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. <i>Cancer Immunology Research</i> , 2016, 4, 779-788.	1.6	80
282	Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. <i>Gynecologic Oncology</i> , 2016, 142, 548-556.	0.6	80
283	6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 731-743.	2.6	39
284	Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS α -p110 crosstalk. <i>Nature Communications</i> , 2016, 7, 11672.	5.8	38
285	Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT α -NF- κ B α -CXCL5 signaling. <i>Scientific Reports</i> , 2016, 6, 37085.	1.6	29
286	PARP inhibitor combination therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 73-85.	2.0	175
288	Gambogic Acid and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2016, 928, 375-395.	0.8	22
289	Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX. <i>Translational Oncology</i> , 2016, 9, 458-465.	1.7	9
290	Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models. <i>International Journal of Oncology</i> , 2016, 49, 207-216.	1.4	13
291	The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3K β / γ inhibitor. <i>EJNMMI Research</i> , 2016, 6, 62.	1.1	13

#	ARTICLE	IF	CITATIONS
292	Chorein Sensitive Orai1 Expression and Store Operated Ca ²⁺ Entry in Rhabdomyosarcoma Cells. <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 1141-1152.	1.1	25
293	Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias. <i>European Journal of Cancer</i> , 2016, 63, 74-87.	1.3	13
294	Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer. <i>BMC Systems Biology</i> , 2016, 10, 33.	3.0	13
295	C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor. <i>Tumor Biology</i> , 2016, 37, 11039-11048.	0.8	16
296	Aldehyde dehydrogenase 2 deficiency blunts compensatory cardiac hypertrophy through modulating Akt phosphorylation early after transverse aorta constriction in mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 1587-1593.	1.8	20
297	Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains. <i>Oncogenesis</i> , 2016, 5, e228-e228.	2.1	20
298	PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics. <i>Cancer Drug Discovery and Development</i> , 2016, , 1-25.	0.2	0
299	Genetic variants in glucose-6-phosphate isomerase gene as prognosis predictors in hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 698-704.	0.7	13
300	Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085) Tj ETQq0 0 0 rgBT /Overlock 10 e309-e316.	2.2	50
301	Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats. <i>Journal of Neuro-Oncology</i> , 2016, 129, 57-66.	1.4	25
302	Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor. <i>International Journal of Cancer</i> , 2016, 139, 700-711.	2.3	5
303	Recent insights into endothelial control of leukocyte extravasation. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1591-1608.	2.4	25
304	Breakthrough therapies in B-cell non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2016, 27, 778-787.	0.6	38
305	Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases. <i>Modern Pathology</i> , 2016, 29, 275-282.	2.9	42
306	Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2874-2884.	3.2	103
307	Discovery of imidazo[1,2- a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 742-746.	1.0	26
308	Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 540-545.	3.2	85
309	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1583-1591.	3.2	86

#	ARTICLE	IF	CITATIONS
310	PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 13-26.	1.6	66
311	RAS isoforms and mutations in cancer at a glance. <i>Journal of Cell Science</i> , 2016, 129, 1287-92.	1.2	606
312	Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3K β / γ inhibitors for the treatment of PTEN-deficient tumours. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2318-2323.	1.0	7
313	Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms. <i>Cancer Cell</i> , 2016, 29, 523-535.	7.7	89
314	Molecular profiling of head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1625-38.	0.9	79
315	Emerging therapeutic targets in metastatic progression: A focus on breast cancer. , 2016, 161, 79-96.		53
316	Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K α and PI3K β , Demonstrates Treatment Strategies for PI3KCA-Dependent Breast Cancers. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 877-889.	1.9	38
317	Pharmacological inhibitors of autophagy as novel cancer therapeutic agents. <i>Pharmacological Research</i> , 2016, 105, 164-175.	3.1	83
318	PP2A as a master regulator of the cell cycle. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2016, 51, 162-184.	2.3	263
319	Nonalcoholic fatty liver disease and hepatocellular carcinoma. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1151-1160.	1.5	143
320	Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 648-654.	1.2	69
321	N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 41.	3.5	8
322	Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>OncImmunology</i> , 2016, 5, e1149674.	2.1	46
323	Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold. <i>Journal of Computer-Aided Molecular Design</i> , 2016, 30, 323-330.	1.3	11
324	Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment. <i>Cancer Letters</i> , 2016, 372, 128-136.	3.2	10
325	The histone demethylase JMJD2A/KDM4A links ribosomal RNA transcription to nutrients and growth factors availability. <i>Nature Communications</i> , 2016, 7, 10174.	5.8	31
326	Autophagy inhibitors. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 985-1001.	2.4	231
327	Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. <i>Advanced Drug Delivery Reviews</i> , 2016, 104, 93-109.	6.6	77

#	ARTICLE	IF	CITATIONS
328	Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2744-2754.	3.2	52
329	Mechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors. , 2016, , 227-272.		1
330	Clinical relevance of autophagic therapy in cancer: Investigating the current trends, challenges, and future prospects. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 228-252.	2.7	17
331	“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 3-18.	6.6	399
332	Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy <i>in Vivo</i> . <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 72-76.	1.3	46
333	FOXO factors and breast cancer: outfoxing endocrine resistance. <i>Endocrine-Related Cancer</i> , 2016, 23, R113-R130.	1.6	39
334	An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 15-30.	1.9	8
335	Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. <i>Clinical Cancer Research</i> , 2016, 22, 383-394.	3.2	21
336	Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An <i>in Vitro</i> comparative study. <i>Experimental Hematology</i> , 2016, 44, 38-49.e1.	0.2	6
337	The disulfide compound γ -lipoic acid and its derivatives: A novel class of anticancer agents targeting mitochondria. <i>Cancer Letters</i> , 2016, 371, 12-19.	3.2	99
338	The role of natural polyphenols in cell signaling and cytoprotection against cancer development. <i>Journal of Nutritional Biochemistry</i> , 2016, 32, 1-19.	1.9	119
339	Fangchinoline suppresses the growth and invasion of human glioblastoma cells by inhibiting the kinase activity of Akt and Akt-mediated signaling cascades. <i>Tumor Biology</i> , 2016, 37, 2709-2719.	0.8	14
340	Preclinical <i>In Vitro</i> , <i>In Vivo</i> , and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers. <i>Cancer Prevention Research</i> , 2016, 9, 63-73.	0.7	9
341	PI3K-p110 α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. <i>Oncogene</i> , 2016, 35, 3607-3612.	2.6	38
342	Phosphoinositides: Important lipids in the coordination of cell dynamics. <i>Biochimie</i> , 2016, 125, 250-258.	1.3	86
343	Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent. <i>Tumor Biology</i> , 2016, 37, 1025-1033.	0.8	8
344	Inhibition of breast cancer invasion by TIS21/BTG2/Pc3-Akt1-Sp1-Nox4 pathway targeting actin nucleators, mDia genes. <i>Oncogene</i> , 2016, 35, 83-93.	2.6	34
345	hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. <i>Oncogene</i> , 2016, 35, 887-896.	2.6	13

#	ARTICLE	IF	CITATIONS
346	Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycle. <i>Small GTPases</i> , 2017, 8, 20-25.	0.7	10
347	Discovery of a Phosphoinositide 3-Kinase (PI3K) Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3K Potency in a PI3K-Selective Template by Targeting Nonconserved Asp856. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1555-1567.	2.9	27
348	Strategies to overcome therapeutic resistance in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 102-110.	0.8	35
349	Targeted Therapy and Immunosuppression in the Tumor Microenvironment. <i>Trends in Cancer</i> , 2017, 3, 19-27.	3.8	57
350	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 76-87.	1.9	69
351	Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate. <i>Scientific Reports</i> , 2017, 7, 39985.	1.6	16
352	Silibinin Treatment Inhibits the Growth of Hedgehog Inhibitor-Resistant Basal Cell Carcinoma Cells via Targeting EGFR, MAPK, Akt and Hedgehog Signaling. <i>Photochemistry and Photobiology</i> , 2017, 93, 999-1007.	1.3	22
353	Acute myeloid leukemia – strategies and challenges for targeting oncogenic Hedgehog/GLI signaling. <i>Cell Communication and Signaling</i> , 2017, 15, 8.	2.7	47
354	Induction of dormancy in hypoxic human papillomavirus-positive cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E990-E998.	3.3	49
355	The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors. <i>Nature Cell Biology</i> , 2017, 19, 238-251.	4.6	201
356	Overexpression of HepaCAM inhibits bladder cancer cell proliferation and viability through the AKT/FoxO pathway. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 793-805.	1.2	30
357	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , 2017, 7, 43013.	1.6	44
358	Mycolates of Mycobacterium tuberculosis modulate the flow of cholesterol for bacillary proliferation in murine macrophages. <i>Journal of Lipid Research</i> , 2017, 58, 709-718.	2.0	17
359	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 448-453.	2.0	26
360	Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity. <i>Scientific Reports</i> , 2017, 7, 42700.	1.6	32
361	Mechanisms of Drug Resistance in Melanoma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 91-108.	0.9	63
362	New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors. <i>Oral Oncology</i> , 2017, 67, 119-123.	0.8	20
363	Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 13-30.	0.9	8

#	ARTICLE	IF	CITATIONS
364	Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma. <i>Head and Neck</i> , 2017, 39, 1145-1154.	0.9	13
365	Hepatic Activation of the FAM3C-HSF1-CaM Pathway Attenuates Hyperglycemia of Obese Diabetic Mice. <i>Diabetes</i> , 2017, 66, 1185-1197.	0.3	33
366	TGF- β 2 Family Signaling in Tumor Suppression and Cancer Progression. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a022277.	2.3	345
367	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 177-187.	0.6	138
368	LncRNA AK023948 is a positive regulator of AKT. <i>Nature Communications</i> , 2017, 8, 14422.	5.8	92
369	Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 439-450.	1.1	47
370	Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line. <i>Scientific Reports</i> , 2017, 7, 46079.	1.6	23
371	The mechanism of epithelial-mesenchymal transition induced by TGF- β 1 in neuroblastoma cells. <i>International Journal of Oncology</i> , 2017, 50, 1623-1633.	1.4	26
372	New Challenges in Cancer Therapy: MAPK Inhibitors from Bench to Bedside. , 2017, , 67-91.		1
373	Regulation of AGR2 expression via 3'UTR shortening. <i>Experimental Cell Research</i> , 2017, 356, 40-47.	1.2	12
374	Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4023-4035.	2.9	29
375	Crosstalk between STAT5 activation and PI3K/AKT functions in normal and transformed mammary epithelial cells. <i>Molecular and Cellular Endocrinology</i> , 2017, 451, 31-39.	1.6	65
376	Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3K/mTOR inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3117-3122.	1.0	10
377	Enrichment of PI3K-AKT/mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4919-4928.	3.2	74
378	ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. <i>Molecular Cancer</i> , 2017, 16, 79.	7.9	452
379	Connecting the dots: Overlaps between autism and cancer suggest possible common mechanisms regarding signaling pathways related to metabolic alterations. <i>Medical Hypotheses</i> , 2017, 103, 118-123.	0.8	18
380	Design and Synthesis of Soluble and Cell-Permeable PI3K Inhibitors for Long-Acting Inhaled Administration. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5057-5071.	2.9	21
381	Design, synthesis, molecular modeling and anticholinesterase activity of benzylidene-benzofuran-3-ones containing cyclic amine side chain. <i>Future Medicinal Chemistry</i> , 2017, 9, 659-671.	1.1	39

#	ARTICLE	IF	CITATIONS
382	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3K β Isoform Inhibitor, in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 5015-5023.	3.2	65
383	Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase β (PI3K β) Inhibitor for the Treatment of Immunological Disorders. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5193-5208.	2.9	22
384	Control of B lymphocyte development and functions by the mTOR signaling pathways. <i>Cytokine and Growth Factor Reviews</i> , 2017, 35, 47-62.	3.2	42
385	Stressor-driven extracellular acidosis as tumor inducer via aberrant enzyme activation: A review on the mechanisms and possible prophylaxis. <i>Gene</i> , 2017, 626, 209-214.	1.0	17
386	Evidence of the immunomodulatory role of dual PI3K/mTOR inhibitors in transplantation: an experimental study in mice. <i>Transplant International</i> , 2017, 30, 1061-1074.	0.8	7
387	Oncogenic Roles of the PI3K/AKT/mTOR Axis. <i>Current Topics in Microbiology and Immunology</i> , 2017, 407, 153-189.	0.7	242
388	Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 385-392.	1.0	38
389	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	9
390	Blockade of GLUT1 by WZB117 resensitizes breast cancer cells to adriamycin. <i>Anti-Cancer Drugs</i> , 2017, 28, 880-887.	0.7	38
391	Calycosin Enhances Some Chemotherapeutic Drugs Inhibition of Akt Signaling Pathway in Gastric Cells. <i>Cancer Investigation</i> , 2017, 35, 289-300.	0.6	14
392	PI3K signaling in cancer: beyond AKT. <i>Current Opinion in Cell Biology</i> , 2017, 45, 62-71.	2.6	364
393	New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 490-498.	1.2	40
394	Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3K β / γ inhibitors for the treatment of PTEN-deficient tumours. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1949-1954.	1.0	4
395	Bayesian Response-Adaptive Designs for Basket Trials. <i>Biometrics</i> , 2017, 73, 905-915.	0.8	38
396	Knockdown of astrocyte elevated gene-1 inhibited cell growth and induced apoptosis and suppressed invasion in ovarian cancer cells. <i>Gene</i> , 2017, 616, 8-15.	1.0	17
397	Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110 β as a Therapeutic Approach to Treat Non-Hodgkin's B Cell Malignancies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 361, 312-321.	1.3	7
398	The challenge of targeting cancer stem cells to halt metastasis. <i>Seminars in Cancer Biology</i> , 2017, 44, 25-42.	4.3	154
399	Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). <i>Leukemia</i> , 2017, 31, 1872-1881.	3.3	59

#	ARTICLE	IF	CITATIONS
400	Current Trends in Cancer Therapy. , 2017, , 1-24.		7
401	Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition. <i>Oncogene</i> , 2017, 36, 2762-2774.	2.6	24
402	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. <i>Oncogene</i> , 2017, 36, 2737-2749.	2.6	34
403	Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. <i>Pharmacological Research</i> , 2017, 117, 20-31.	3.1	78
404	Identification of novel PI3K inhibitors through a scaffold hopping strategy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4794-4799.	1.0	5
405	EGF regulation of proximal tubule cell proliferation and VEGF-A secretion. <i>Physiological Reports</i> , 2017, 5, e13453.	0.7	22
406	PIP-ing Lipids on Membranes: PTEN Takes the Cake. <i>Molecular Cell</i> , 2017, 68, 471-472.	4.5	0
407	Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p -aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings. <i>European Journal of Medicinal Chemistry</i> , 2017, 141, 721-733.	2.6	14
408	A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2017, 22, 1491-1499.	1.9	23
409	A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2819-2828.	1.3	28
410	EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy. <i>Nanoscale</i> , 2017, 9, 16365-16374.	2.8	98
411	20(s)-Protopanaxadiol (PPD) increases the radiotherapy sensitivity of laryngeal carcinoma. <i>Food and Function</i> , 2017, 8, 4469-4477.	2.1	7
412	Development of highly sensitive cell-based AKT kinase ELISA for monitoring PI3K beta activity and compound efficacy. <i>Journal of Immunoassay and Immunochemistry</i> , 2017, 38, 663-674.	0.5	2
413	mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability. <i>Cancer Cell</i> , 2017, 32, 624-638.e5.	7.7	109
414	PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K. <i>Molecular Cell</i> , 2017, 68, 566-580.e10.	4.5	149
415	Lithium Sensitivity of Store Operated Ca ²⁺ Entry and Survival of Fibroblasts Isolated from Chorea-Acanthocytosis Patients. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 2066-2077.	1.1	24
416	hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells. <i>Nucleic Acids Research</i> , 2017, 45, 12270-12284.	6.5	57
417	AKT2 suppresses pro-survival autophagy triggered by DNA double-strand breaks in colorectal cancer cells. <i>Cell Death and Disease</i> , 2017, 8, e3019-e3019.	2.7	44

#	ARTICLE	IF	CITATIONS
418	Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2422-2431.	1.9	30
419	Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors. <i>Analytical Chemistry</i> , 2017, 89, 10592-10600.	3.2	30
420	Targeting androgen-independent pathways: new chances for patients with prostate cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 42-53.	2.0	25
421	Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications. <i>Modern Pathology</i> , 2017, 30, 1633-1641.	2.9	41
422	Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. <i>Journal of Hepatology</i> , 2017, 67, 1194-1203.	1.8	77
423	Hydrogen sulfide acts as a double-edged sword in human hepatocellular carcinoma cells through EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways. <i>Scientific Reports</i> , 2017, 7, 5134.	1.6	93
424	A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells. <i>Cancer Letters</i> , 2017, 405, 1-9.	3.2	7
425	Improving pharmacological targeting of AKT in melanoma. <i>Cancer Letters</i> , 2017, 404, 29-36.	3.2	9
426	Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition. <i>Molecular Cell</i> , 2017, 67, 512-527.e4.	4.5	40
427	Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 875-880.	1.3	28
428	Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. <i>Scientific Reports</i> , 2017, 7, 7066.	1.6	68
429	Lithium Sensitive ORAI1 Expression, Store Operated Ca ²⁺ Entry and Suicidal Death of Neurons in Chorea-Acanthocytosis. <i>Scientific Reports</i> , 2017, 7, 6457.	1.6	31
431	ErbB2-positive mammary tumors can escape PI3K-p110 α loss through downregulation of the Pten tumor suppressor. <i>Oncogene</i> , 2017, 36, 6059-6066.	2.6	7
432	Mechanisms underlying the antiproliferative effects of a series of quinoxaline-derived chalcones. <i>Scientific Reports</i> , 2017, 7, 15850.	1.6	13
434	Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. <i>Nature Communications</i> , 2017, 8, 1773.	5.8	54
435	Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism. <i>Nature Communications</i> , 2017, 8, 1804.	5.8	59
436	Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. <i>Genes and Development</i> , 2017, 31, 2067-2084.	2.7	57
437	MYC and tumor metabolism: chicken and egg. <i>EMBO Journal</i> , 2017, 36, 3409-3420.	3.5	180

#	ARTICLE	IF	CITATIONS
438	PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1095-1103.	0.8	99
439	Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2017, 102, 2104-2112.	1.7	41
440	Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 189-198.	1.3	34
442	Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation. <i>Oncogene</i> , 2017, 36, 6262-6271.	2.6	38
443	Mitochondria on the move: emerging paradigms of organelle trafficking in tumour plasticity and metastasis. <i>British Journal of Cancer</i> , 2017, 117, 301-305.	2.9	49
444	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. <i>Breast</i> , 2017, 34, S19-S26.	0.9	46
445	Targeting the mTOR pathway in breast cancer. <i>Tumor Biology</i> , 2017, 39, 101042831771082.	0.8	20
446	27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer. <i>Chemistry and Physics of Lipids</i> , 2017, 207, 108-126.	1.5	41
447	A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote Sonic Hedgehog medulloblastoma. <i>Oncogene</i> , 2017, 36, 5969-5984.	2.6	42
448	Idelalisib may have the potential to increase radiotherapy side effects. <i>Radiation Oncology</i> , 2017, 12, 109.	1.2	5
449	PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. <i>Molecular Cancer</i> , 2017, 16, 93.	7.9	18
450	Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer. <i>Cell Death and Differentiation</i> , 2017, 24, 15-25.	5.0	50
451	Non-Smad Signaling Pathways of the TGF- β Family. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a022129.	2.3	496
452	Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors $\text{HIF}^{1\alpha}$ and $\text{HIF}^{2\alpha}$. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 153-161.	0.9	91
453	The challenges of tumor genetic diversity. <i>Cancer</i> , 2017, 123, 917-927.	2.0	67
454	Brassinosteroid Insensitive 2 (BIN2) acts as a downstream effector of the Target of Rapamycin (TOR) signaling pathway to regulate photoautotrophic growth in Arabidopsis. <i>New Phytologist</i> , 2017, 213, 233-249.	3.5	93
455	Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. <i>Acta Pharmaceutica Sinica B</i> , 2017, 7, 27-37.	5.7	120
456	Mechanisms of l-Arginine-Auxotrophic Response and Their Cancer Therapeutic Implications. , 2017, , 563-575.		0

#	ARTICLE	IF	CITATIONS
457	The Many Roles of Ral GTPases in Ras-Driven Cancer. , 2017, , 41-59.		0
458	Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. American Journal of Respiratory and Critical Care Medicine. 2017. 195. 425-437.	2.5	117
459	Functional characterization of a novel somatic oncogenic mutation of PIK3CB. Signal Transduction and Targeted Therapy, 2017, 2, 17063.	7.1	28
460	ErbB2 Receptor in Breast Cancer: Implications in Cancer Cell Migration, Invasion and Resistance to Targeted Therapy. , 0, , .		3
461	Targeting PDK1 for Chemosensitization of Cancer Cells. Cancers, 2017, 9, 140.	1.7	48
462	Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update. International Journal of Molecular Sciences, 2017, 18, 2423.	1.8	59
463	Emerging Cytotoxic Alkaloids in the Battle against Cancer: Overview of Molecular Mechanisms. Molecules, 2017, 22, 250.	1.7	102
464	Ginsenoside PPD TM s Antitumor Effect via Down-Regulation of mTOR Revealed by Super-Resolution Imaging. Molecules, 2017, 22, 486.	1.7	12
465	Drug discovery. , 2017, , 281-420.		1
466	Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment. Cancers, 2017, 9, 24.	1.7	31
467	AR Signaling and the PI3K Pathway in Prostate Cancer. Cancers, 2017, 9, 34.	1.7	118
468	The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2017, 18, 210.	1.8	20
469	The Selective Phosphoinositide-3-Kinase p110 β Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation. Frontiers in Immunology, 2017, 8, 747.	2.2	21
470	The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma. Frontiers in Oncology, 2017, 7, 312.	1.3	17
471	Questioning the role of selected somatic PIK3C2B mutations in squamous non-small cell lung cancer oncogenesis. PLoS ONE, 2017, 12, e0187308.	1.1	7
472	XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis. BMC Cancer, 2017, 17, 640.	1.1	39
473	CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling. Cancer Cell International, 2017, 17, 113.	1.8	25
474	Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression. Molecular Cancer, 2017, 16, 163.	7.9	47

#	ARTICLE	IF	CITATIONS
475	Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism. <i>Molecular Autism</i> , 2017, 8, 66.	2.6	85
476	Silencing of type IÎ³ phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion. <i>Oncology Reports</i> , 2017, 38, 253-262.	1.2	3
477	Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer. , 2017, , 202-280.		4
478	GABARAPL1 suppresses metastasis by counteracting PI3K/Akt pathway in prostate cancer. <i>Oncotarget</i> , 2017, 8, 4449-4459.	0.8	23
479	The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5491-5524.	1.0	56
480	Molecular biology of human epidermal receptors, signaling pathways and targeted therapy against cancers: new evidences and old challenges. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2017, 53, .	1.2	22
481	Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways. <i>Oncotarget</i> , 2017, 8, 28510-28525.	0.8	56
482	PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways. <i>Oncotarget</i> , 2017, 8, 99901-99912.	0.8	78
483	Effect and mechanism of inhibition of PI3K/Akt/mTOR signal pathway on chronic neuropathic pain and spinal microglia in a rat model of chronic constriction injury. <i>Oncotarget</i> , 2017, 8, 52923-52934.	0.8	46
484	High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 1002-1011.	0.6	7
485	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin. <i>Scientific Reports</i> , 2018, 8, 3317.	1.6	46
486	Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway. <i>Oral Oncology</i> , 2018, 79, 55-63.	0.8	54
487	Targeting the PI3K pathway in cancer: are we making headway?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 273-291.	12.5	762
488	PI3K/Akt Cooperates with Oncogenic Notch by Inducing Nitric Oxide-Dependent Inflammation. <i>Cell Reports</i> , 2018, 22, 2541-2549.	2.9	61
489	LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85. <i>Cancer Letters</i> , 2018, 420, 38-48.	3.2	46
490	Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 51-62.	1.0	5
491	Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells. <i>Cancer Medicine</i> , 2018, 7, 1275-1284.	1.3	9
492	Elevated RTP801 promotes cell proliferation in non-small cell lung cancer. <i>IUBMB Life</i> , 2018, 70, 310-319.	1.5	6

#	ARTICLE	IF	CITATIONS
493	Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma. <i>Oncogene</i> , 2018, 37, 2630-2644.	2.6	37
495	Molecular Substantiation and Drug Efficacy of Relatively High Molecular Weight Sâ€BINOLs; Appraised as Breast Cancer Medication and PI3Kinase Inhibitors. <i>Journal of Heterocyclic Chemistry</i> , 2018, 55, 1339-1345.	1.4	10
497	Resistance of Colorectal Tumors to Anti-EGFR Antibodies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 1-27.	0.1	1
498	Mechanisms of Resistance to PI3K and AKT Inhibitors. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 117-146.	0.1	3
499	Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptorâ€positive advanced breast cancer. <i>Cancer Science</i> , 2018, 109, 1592-1601.	1.7	24
500	HER2-positive breast cancer: Current and new therapeutic strategies. <i>Breast</i> , 2018, 39, 80-88.	0.9	89
501	Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. <i>Nature Communications</i> , 2018, 9, 1357.	5.8	100
502	Chemical probes and drug leads from advances in synthetic planning and methodology. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 333-352.	21.5	182
503	Update on PARP Inhibitors in Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 21.	1.3	92
504	Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation. <i>Biochemical Pharmacology</i> , 2018, 150, 72-85.	2.0	49
505	Linkage of Metabolic Defects to Activated <i>PIK3CA</i> Alleles in Endothelial Cells Derived from Lymphatic Malformation. <i>Lymphatic Research and Biology</i> , 2018, 16, 43-55.	0.5	24
506	PIK3R3 regulates PPARÎ± expression to stimulate fatty acid Î²-oxidation and decrease hepatosteatosis. <i>Experimental and Molecular Medicine</i> , 2018, 50, e431-e431.	3.2	32
507	Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 637-646.	1.4	5
508	PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. <i>Leukemia and Lymphoma</i> , 2018, 59, 2524-2534.	0.6	54
509	Targeted AKT Inhibition in Prostate Cancer Cells and Spheroids Reduces Aerobic Glycolysis and Generation of Hyperpolarized [1-13C] Lactate. <i>Molecular Cancer Research</i> , 2018, 16, 453-460.	1.5	16
510	Discovering new PI3KÎ± inhibitors with a strategy of combining ligand-based and structure-based virtual screening. <i>Journal of Computer-Aided Molecular Design</i> , 2018, 32, 347-361.	1.3	20
511	Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 3-16.	1.9	81
512	Translational control of aberrant stress responses as a hallmark of cancer. <i>Journal of Pathology</i> , 2018, 244, 650-666.	2.1	65

#	ARTICLE	IF	CITATIONS
513	Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer. <i>Bioscience Reports</i> , 2018, 38, .	1.1	60
514	Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. <i>Experimental and Molecular Medicine</i> , 2018, 50, e417-e417.	3.2	39
515	The role of RICTOR downstream of receptor tyrosine kinase in cancers. <i>Molecular Cancer</i> , 2018, 17, 39.	7.9	42
516	Natural Stilbenoids Have Anti-Inflammatory Properties <i>in Vivo</i> and Down-Regulate the Production of Inflammatory Mediators NO, IL6, and MCP1 Possibly in a PI3K/Akt-Dependent Manner. <i>Journal of Natural Products</i> , 2018, 81, 1131-1142.	1.5	57
517	How iMALDI can improve clinical diagnostics. <i>Analyst, The</i> , 2018, 143, 2197-2203.	1.7	20
518	Identification of The Aberrantly Expressed LncRNAs in Hepatocellular Carcinoma: A Bioinformatics Analysis Based on RNA-sequencing. <i>Scientific Reports</i> , 2018, 8, 5395.	1.6	26
519	Insight from the maximal activation of the signal transduction excitable network in <i>Dictyostelium discoideum</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3722-E3730.	3.3	16
520	Opposite Interplay Between the Canonical WNT/ β -Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas. <i>Neuroscience Bulletin</i> , 2018, 34, 573-588.	1.5	49
521	PDK1/WNK1 signaling is affected by HBx and involved in the viability and metastasis of hepatic cells. <i>Oncology Letters</i> , 2018, 15, 5940-5946.	0.8	9
522	In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS). <i>Neurogenetics</i> , 2018, 19, 77-91.	0.7	65
523	Discovery of novel quinazolinone derivatives as high potent and selective PI3K β and PI3K δ inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 151, 9-17.	2.6	20
524	PTEN Deficiency and AMPK Activation Promote Nutrient Scavenging and Anabolism in Prostate Cancer Cells. <i>Cancer Discovery</i> , 2018, 8, 866-883.	7.7	141
525	Combining Stochastic Deformation/Relaxation and Intermolecular Contacts Analysis for Extracting Pharmacophores from Ligand-Receptor Complexes. <i>Journal of Chemical Information and Modeling</i> , 2018, 58, 879-893.	2.5	11
526	A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of vixtalib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 36-44.	1.2	10
527	PKB/Akt-dependent regulation of inflammation in cancer. <i>Seminars in Cancer Biology</i> , 2018, 48, 62-69.	4.3	87
528	PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. <i>Seminars in Cancer Biology</i> , 2018, 48, 91-103.	4.3	257
529	Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 2058-2066.	2.0	61
530	Inhibiting 4EBP1 in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 14-21.	3.2	34

#	ARTICLE	IF	CITATIONS
531	PIK3CB/p110 ^β is a selective survival factor for glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 494-505.	0.6	43
532	A drug development perspective on targeting tumor-associated myeloid cells. <i>FEBS Journal</i> , 2018, 285, 763-776.	2.2	31
533	Potential hazards of fenvalerate in massive pollution influence the apoptosis sensitivity. <i>Journal of Applied Toxicology</i> , 2018, 38, 240-247.	1.4	6
534	ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2018, 37, 377-388.	2.6	29
535	PI3K: A Crucial Piece in the RAS Signaling Puzzle. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a031450.	2.9	38
536	Target of rapamycin signaling orchestrates growth-defense tradeoffs in plants. <i>New Phytologist</i> , 2018, 217, 305-319.	3.5	97
537	Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer. <i>Methods in Molecular Biology</i> , 2018, 1655, 335-350.	0.4	117
538	Re-evaluating the role of FOXOs in cancer. <i>Seminars in Cancer Biology</i> , 2018, 50, 90-100.	4.3	136
539	Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. <i>Biochemical Pharmacology</i> , 2018, 148, 13-26.	2.0	38
540	PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. <i>Oncogene</i> , 2018, 37, 341-351.	2.6	98
541	Novel agents for relapsed and refractory follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 41-48.	0.7	19
542	Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 1796-1811.	2.0	28
544	Aberrant RNA Splicing in Cancer and Drug Resistance. <i>Cancers</i> , 2018, 10, 458.	1.7	145
545	Inhibition of Lithium Sensitive Orai1/ STIM1 Expression and Store Operated Ca ²⁺ Entry in Chorea-Acanthocytosis Neurons by NF- κ B Inhibitor Wogonin. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 278-289.	1.1	9
546	Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. <i>Oncotarget</i> , 2018, 9, 8027-8041.	0.8	42
547	Zuo Jin Wan Reverses DDP Resistance in Gastric Cancer through ROCK/PTEN/PI3K Signaling Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-11.	0.5	8
548	Tanshinol inhibits the growth, migration and invasion of hepatocellular carcinoma cells via regulating the PI3K-AKT signaling pathway. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 87-99.	1.0	20
549	Class I Phosphoinositide 3-Kinase PIK3CA/p110 ^α and PIK3CB/p110 ^β Isoforms in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3931.	1.8	26

#	ARTICLE	IF	CITATIONS
550	Overexpression of PIK3R1 promotes hepatocellular carcinoma progression. <i>Biological Research</i> , 2018, 51, 52.	1.5	32
551	NVP-BE2235 synergizes cisplatin sensitivity in osteosarcoma. <i>Oncotarget</i> , 2018, 9, 10483-10496.	0.8	16
552	PI3K pathway in prostate cancer: All resistant roads lead to PI3K. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 198-206.	3.3	27
553	PI3K Is a Therapeutic Target in Hepatocellular Carcinoma. <i>Hepatology</i> , 2018, 68, 2285-2300.	3.6	35
554	A comprehensive review of protein kinase inhibitors for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1249-1270.	1.1	164
555	Overexpression of MARCKS indicates a poor prognosis of oral squamous cell carcinoma. <i>Oncology Letters</i> , 2018, 16, 5498-5504.	0.8	4
556	Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo. <i>Cellular Physiology and Biochemistry</i> , 2018, 50, 640-653.	1.1	8
557	Metformin reverses the resistance mechanism of lung adenocarcinoma cells that knocks down the Nrf2 gene. <i>Oncology Letters</i> , 2018, 16, 6071-6080.	0.8	14
558	Macrophage migration inhibitory factor contributes to the pathogenesis of benign lymphoepithelial lesion of the lacrimal gland. <i>Cell Communication and Signaling</i> , 2018, 16, 70.	2.7	3
559	Molecular Targets Modulated by Fangchinoline in Tumor Cells and Preclinical Models. <i>Molecules</i> , 2018, 23, 2538.	1.7	32
560	Single-cell barcode analysis provides a rapid readout of cellular signaling pathways in clinical specimens. <i>Nature Communications</i> , 2018, 9, 4550.	5.8	47
561	Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells. <i>Oncology Reports</i> , 2018, 40, 3223-3234.	1.2	18
562	Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma. <i>International Journal of Oncology</i> , 2018, 53, 2531-2541.	1.4	21
563	Targeting glycometabolic reprogramming to restore the sensitivity of leukemia drug-resistant K562/ADM cells to adriamycin. <i>Life Sciences</i> , 2018, 215, 1-10.	2.0	18
564	Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor. <i>Future Medicinal Chemistry</i> , 2018, 10, 2445-2455.	1.1	7
565	Immuno-MALDI (iMALDI) mass spectrometry for the analysis of proteins in signaling pathways. <i>Expert Review of Proteomics</i> , 2018, 15, 701-708.	1.3	8
566	Cancer-Associated PIK3CA Mutations in Overgrowth Disorders. <i>Trends in Molecular Medicine</i> , 2018, 24, 856-870.	3.5	181
567	Comparison of PI3K Pathway in HPV-Associated Oropharyngeal Cancer With and Without Tobacco Exposure. <i>Laryngoscope Investigative Otolaryngology</i> , 2018, 3, 283-289.	0.6	7

#	ARTICLE	IF	CITATIONS
568	First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8353-8373.	2.9	17
569	Quantitative Lipid Imaging Reveals a New Signaling Function of Phosphatidylinositol-3,4-Bisphosphate: Isoform- and Site-Specific Activation of Akt. <i>Molecular Cell</i> , 2018, 71, 1092-1104.e5.	4.5	89
570	Synthesis of Substituted Quinolinyl Ether-based Inhibitors of PI3K as Potential Anticancer Agents. <i>Journal of Heterocyclic Chemistry</i> , 2018, 55, 1669-1677.	1.4	12
571	Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients. <i>Current Problems in Cancer</i> , 2018, 42, 572-581.	1.0	17
572	Increased expression of FHL2 promotes tumorigenesis in cervical cancer and is correlated with poor prognosis. <i>Gene</i> , 2018, 669, 99-106.	1.0	18
573	Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 183, 51-61.	1.2	29
574	Salvianolic acid B inhibits glycolysis in oral squamous cell carcinoma via targeting PI3K/AKT/HIF-1 α signaling pathway. <i>Cell Death and Disease</i> , 2018, 9, 599.	2.7	61
576	Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase β (PI3K β) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5245-5256.	2.9	36
577	Marine natural products for multi-targeted cancer treatment: A future insight. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 233-245.	2.5	50
578	Matrix metalloproteinase (MMP)-7 in Barrett's esophagus and esophageal adenocarcinoma: expression, metabolism, and functional significance. <i>Physiological Reports</i> , 2018, 6, e13683.	0.7	12
579	Insulin suppresses the production of fibroblast growth factor 23 (FGF23). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 5804-5809.	3.3	96
580	Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. <i>Genes and Diseases</i> , 2018, 5, 77-106.	1.5	714
581	Molecular Treatment of High-Grade Gliomas. , 2018, , 419-437.		0
582	Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. <i>Nature Chemical Biology</i> , 2018, 14, 768-777.	3.9	64
583	RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers. <i>Molecular Therapy</i> , 2018, 26, 2019-2033.	3.7	29
585	Atorvastatin Inhibits the HIF1 α -PPAR Axis, Which Is Essential for Maintaining the Function of Human Induced Pluripotent Stem Cells. <i>Molecular Therapy</i> , 2018, 26, 1715-1734.	3.7	14
586	Breast cancer stem cells: Features, key drivers and treatment options. <i>Seminars in Cancer Biology</i> , 2018, 53, 59-74.	4.3	132
587	Eukaryotic elongation factors 2 promotes tumor cell proliferation and correlates with poor prognosis in ovarian cancer. <i>Tissue and Cell</i> , 2018, 53, 53-60.	1.0	19

#	ARTICLE	IF	CITATIONS
588	Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 454.	1.6	7
589	Understanding Key Mechanisms of Exercise-Induced Cardiac Protection to Mitigate Disease: Current Knowledge and Emerging Concepts. <i>Physiological Reviews</i> , 2018, 98, 419-475.	13.1	120
590	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3K γ . <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 4537-4543.	1.4	16
591	Carrier-Free Microspheres of an Anti-Cancer Drug Synthesized via a Sodium Catalyst for Controlled-Release Drug Delivery. <i>Materials</i> , 2018, 11, 281.	1.3	9
592	Restraining Akt1 Phosphorylation Attenuates the Repair of Radiation-Induced DNA Double-Strand Breaks and Reduces the Survival of Irradiated Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2233.	1.8	12
593	Epstein-Barr Virus Susceptibility in Activated PI3K γ Syndrome (APDS) Immunodeficiency. <i>Frontiers in Immunology</i> , 2017, 8, 2005.	2.2	33
594	Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 369.	2.2	79
595	Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 160.	1.3	283
596	PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer. <i>Biomolecules</i> , 2018, 8, 7.	1.8	57
597	Cell-Penetrating CaCO ₃ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma. <i>Cancers</i> , 2018, 10, 31.	1.7	13
598	New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response. <i>Cancers</i> , 2018, 10, 78.	1.7	90
599	PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition. <i>PLoS ONE</i> , 2018, 13, e0200014.	1.1	18
600	Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model. <i>American Journal of Pathology</i> , 2018, 188, 1956-1972.	1.9	52
601	Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K δ -selective inhibitor CYH33 in breast cancer. <i>Cancer Letters</i> , 2018, 433, 273-282.	3.2	15
602	Bergamottin Suppresses Metastasis of Lung Cancer Cells through Abrogation of Diverse Oncogenic Signaling Cascades and Epithelial-to-Mesenchymal Transition. <i>Molecules</i> , 2018, 23, 1601.	1.7	69
603	Buparlisib is a brain penetrable pan-PI3K inhibitor. <i>Scientific Reports</i> , 2018, 8, 10784.	1.6	52
604	PRL-033 promotes gastric cancer peritoneal metastasis via the PI3K/AKT signaling pathway in in vitro and in vivo . <i>Oncology Letters</i> , 2018, 15, 9069-9074.	0.8	14
605	Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 164-172.	1.8	33

#	ARTICLE	IF	CITATIONS
606	PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways. <i>BMC Cancer</i> , 2018, 18, 499.	1.1	31
607	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. <i>Pharmacological Research</i> , 2018, 135, 239-258.	3.1	154
608	Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma secretory senescence. <i>Cell Communication and Signaling</i> , 2018, 16, 48.	2.7	50
609	The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations. <i>Current Cancer Drug Targets</i> , 2018, 18, 355-364.	0.8	23
610	Oridonin inhibits aberrant AKT activation in breast cancer. <i>Oncotarget</i> , 2018, 9, 23878-23889.	0.8	11
611	The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 185-197.	3.3	40
612	The tuberous sclerosis complex subunit TBC1D7 is stabilized by Akt phosphorylation-mediated 14-3-3 binding. <i>Journal of Biological Chemistry</i> , 2018, 293, 16142-16159.	1.6	11
613	MKRN2 inhibits migration and invasion of non-small-cell lung cancer by negatively regulating the PI3K/Akt pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 189.	3.5	34
614	Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 529-538.	1.0	13
615	BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating β -catenin/ZEB1 regulatory loop. <i>Chemico-Biological Interactions</i> , 2018, 294, 18-27.	1.7	9
616	Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy. <i>PLoS ONE</i> , 2018, 13, e0190854.	1.1	42
617	Pharmacological inactivation of the PI3K p110 β prevents breast tumour progression by targeting cancer cells and macrophages. <i>Cell Death and Disease</i> , 2018, 9, 678.	2.7	37
618	TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 4126-4137.	0.4	109
619	Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 639-653.	1.5	14
620	KDM6B Counteracts EZH2-Mediated Suppression of <i>IGFBP5</i> to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1973-1983.	1.9	35
621	Novel role of Gi1±2 in cell migration: Downstream of PI3K kinase-AKT and Rac1 in prostate cancer cells. <i>Journal of Cellular Physiology</i> , 2019, 234, 802-815.	2.0	12
622	The role of PIP5K1±/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1± inhibitor. <i>Oncogene</i> , 2019, 38, 375-389.	2.6	29
623	Amelioration of hepatic function, oxidative stress, and histopathologic damages by <i>Cassia fistula</i> L. fraction in thioacetamide-induced liver toxicity. <i>Environmental Science and Pollution Research</i> , 2019, 26, 29930-29945.	2.7	22

#	ARTICLE	IF	CITATIONS
624	Paeonol induces cytoprotective autophagy via blocking the Akt/mTOR pathway in ovarian cancer cells. <i>Cell Death and Disease</i> , 2019, 10, 609.	2.7	62
625	T and B cell signaling in activated PI3K delta syndrome: From immunodeficiency to autoimmunity. <i>Immunological Reviews</i> , 2019, 291, 154-173.	2.8	51
626	AKT-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression. <i>Oncogene</i> , 2019, 38, 6723-6736.	2.6	21
627	A network pharmacology-based study on the anti-hepatoma effect of Radix Salviae Miltiorrhizae. <i>Chinese Medicine</i> , 2019, 14, 27.	1.6	14
628	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 121-133.	1.1	4
629	Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz004.	0.4	8
630	PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. <i>Seminars in Cancer Biology</i> , 2019, 59, 125-132.	4.3	627
631	Discovery of a novel phosphoinositide 3-kinase gamma (PI3K γ) inhibitor against hematologic malignancies and theoretical studies on its PI3K γ -specific binding mechanisms. <i>RSC Advances</i> , 2019, 9, 20207-20215.	1.7	15
632	PI3K-AKT-mTOR and NF κ B Pathways in Ovarian Cancer: Implications for Targeted Therapeutics. <i>Cancers</i> , 2019, 11, 949.	1.7	109
633	Single nucleotide polymorphism of PIK3CA and its interaction with the environment are risk factors for Chinese Han ovarian cancer. <i>Pathology Research and Practice</i> , 2019, 215, 152520.	1.0	7
634	Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. <i>FEBS Journal</i> , 2019, 286, 3510-3539.	2.2	33
635	Theoretical studies on the selectivity mechanisms of PI3K γ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation. <i>Journal of Molecular Modeling</i> , 2019, 25, 242.	0.8	22
636	Recent advances in microfluidic methods in cancer liquid biopsy. <i>Biomicrofluidics</i> , 2019, 13, 041503.	1.2	39
637	A Brief Overview of the Antitumoral Actions of Leelamine. <i>Biomedicines</i> , 2019, 7, 53.	1.4	14
638	Cervical Glandular Neoplasia. <i>Surgical Pathology Clinics</i> , 2019, 12, 281-313.	0.7	9
639	Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 689-698.	0.2	14
640	Host-induced gene silencing of BcTOR in <i>Botrytis cinerea</i> enhances plant resistance to grey mould. <i>Molecular Plant Pathology</i> , 2019, 20, 1722-1739.	2.0	35
641	Effects of Astragaloside IV on treatment of breast cancer cells execute possibly through regulation of Nrf2 via PI3K/AKT/mTOR signaling pathway. <i>Food Science and Nutrition</i> , 2019, 7, 3403-3413.	1.5	20

#	ARTICLE	IF	CITATIONS
642	Inhibition of TFF3 Enhances Sensitivity and Overcomes Acquired Resistance to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma. <i>Cancers</i> , 2019, 11, 1528.	1.7	14
643	Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PI3KCA and GRB2. <i>Scientific Reports</i> , 2019, 9, 16647.	1.6	8
644	ACVR1 Function in Health and Disease. <i>Cells</i> , 2019, 8, 1366.	1.8	47
645	Profilin 2 Promotes Proliferation and Metastasis of Head and Neck Cancer Cells by Regulating PI3K/AKT/ β -Catenin Signaling Pathway. <i>Oncology Research</i> , 2019, 27, 1079-1088.	0.6	19
646	Ellagic acid, extracted from <i>Sanguisorba officinalis</i> , induces G1 arrest by modulating PTEN activity in B16F10 melanoma cells. <i>Genes To Cells</i> , 2019, 24, 688-704.	0.5	15
647	ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p53 Deficient Cancer Cells and Influence Platinum Sensitivity. <i>Cells</i> , 2019, 8, 1271.	1.8	12
648	Tackling MARCKS-PIP3 circuit attenuates fibroblast activation and fibrosis progression. <i>FASEB Journal</i> , 2019, 33, 14354-14369.	0.2	13
649	For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors. <i>Biomolecules</i> , 2019, 9, 402.	1.8	16
650	Effects of inhibiting the PI3K/Akt/mTOR signaling pathway on the pain of sciatic endometriosis in a rat model. <i>Canadian Journal of Physiology and Pharmacology</i> , 2019, 97, 963-970.	0.7	32
651	Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis. <i>Neoplasia</i> , 2019, 21, 974-988.	2.3	9
652	Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review). <i>Molecular Medicine Reports</i> , 2019, 19, 4529-4535.	1.1	111
653	Cytosolic phospholipase A2 modulates cell-matrix adhesion via the FAK/paxillin pathway in hepatocellular carcinoma. <i>Cancer Biology and Medicine</i> , 2019, 16, 377.	1.4	15
654	PI3K inhibition reduces murine and human liver fibrogenesis in precision-cut liver slices. <i>Biochemical Pharmacology</i> , 2019, 169, 113633.	2.0	17
655	Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3K inhibition in medulloblastoma. <i>Scientific Reports</i> , 2019, 9, 12822.	1.6	24
656	Inhibition of AKT Sensitizes Cancer Cells to Antineoplastic Drugs by Downregulating Flap Endonuclease 1. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2407-2420.	1.9	9
657	Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl Pyrimidine Moiety. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1473-1479.	1.3	28
658	Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivatives containing piperazine as inhibitors of PI3K. <i>Bioorganic Chemistry</i> , 2019, 92, 103238.	2.0	7
659	Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4472.	1.8	283

#	ARTICLE	IF	CITATIONS
660	Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy. <i>Cancers</i> , 2019, 11, 1465.	1.7	50
661	Î±-Humulene inhibits hepatocellular carcinoma cell proliferation and induces apoptosis through the inhibition of Akt signaling. <i>Food and Chemical Toxicology</i> , 2019, 134, 110830.	1.8	37
662	PIK3CD induces cell growth and invasion by activating AKT/GSK-3Î²/Î²-catenin signaling in colorectal cancer. <i>Cancer Science</i> , 2019, 110, 997-1011.	1.7	43
663	New roles for B cell receptor associated kinases: when the B cell is not the target. <i>Leukemia</i> , 2019, 33, 576-587.	3.3	26
664	CXCL13/CXCR5 Axis Predicts Poor Prognosis and Promotes Progression Through PI3K/AKT/mTOR Pathway in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 682.	1.3	70
665	Membrane metalloendopeptidase mediates cellular senescence induced by oncogenic PIK3CA ^{H1047R} accompanied with pro-tumorigenic secretome. <i>International Journal of Cancer</i> , 2019, 145, 817-829.	2.3	8
666	PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2303-2313.	1.6	103
667	Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3. <i>Chemico-Biological Interactions</i> , 2019, 302, 101-107.	1.7	11
668	Phase I study of alpelisib (BYL719), an Î±-specific PI3K inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2019, 110, 1021-1031.	1.7	40
669	The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 522-528.	0.4	13
670	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6992-7014.	2.9	58
671	Serine Protease from <i>Nereis virens</i> Inhibits H1299 Lung Cancer Cell Proliferation via the PI3K/AKT/mTOR Pathway. <i>Marine Drugs</i> , 2019, 17, 366.	2.2	12
672	Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K/Akt signaling in gastric cancer. <i>Cancer Medicine</i> , 2019, 8, 4766-4781.	1.3	201
673	Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3KÎ± Inhibitor TAK-117 in Preclinical Bladder Cancer Models. <i>Molecular Cancer Research</i> , 2019, 17, 1931-1944.	1.5	23
674	Embryonic stem cell microenvironment suppresses the malignancy of cutaneous melanoma cells by down-regulating PI3K/AKT pathway. <i>Cancer Medicine</i> , 2019, 8, 4265-4277.	1.3	9
675	Revisiting mTOR inhibitors as anticancer agents. <i>Drug Discovery Today</i> , 2019, 24, 2086-2095.	3.2	18
676	Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer. <i>Drug Metabolism and Personalized Therapy</i> , 2019, 34, .	0.3	3
677	Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 114930.	1.4	11

#	ARTICLE	IF	CITATIONS
678	Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2703.	1.8	150
679	Exogenous Hydrogen Sulfide Regulates the Growth of Human Thyroid Carcinoma Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-18.	1.9	32
680	M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22/PI3K/AKT signaling. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3051-3063.	1.0	64
681	Antitumor Activities of Secondary Metabolites from Marine Microbe Stress Responses to Virus Infection. , 2019, , 285-318.		0
682	Emerging Role of SOX Proteins in Breast Cancer Development and Maintenance. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 213-230.	1.0	24
683	PI3K isoforms in cell signalling and vesicle trafficking. <i>Nature Reviews Molecular Cell Biology</i> , 2019, 20, 515-534.	16.1	316
684	LncRNA TPT1AS1 promotes tumorigenesis and metastasis in epithelial ovarian cancer by inducing TPT1 expression. <i>Cancer Science</i> , 2019, 110, 1587-1598.	1.7	49
685	PI3K Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction. <i>Journal of the American Heart Association</i> , 2019, 8, e010961.	1.6	15
686	Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway. <i>Leukemia and Lymphoma</i> , 2019, 60, 2697-2704.	0.6	20
687	Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential. <i>Biomolecules</i> , 2019, 9, 174.	1.8	167
688	Effects of PI3K Inhibition on Afucosylated Antibody-Driven Fcγ3R1 Events and Phospho-S6 Activity in NK Cells. <i>Journal of Immunology</i> , 2019, 203, 137-147.	0.4	1
689	The unconventional role of Akt1 in the advanced cancers and in diabetes-promoted carcinogenesis. <i>Pharmacological Research</i> , 2019, 145, 104270.	3.1	45
690	Modulating autophagy as a therapeutic strategy for the treatment of paediatric high-grade glioma. <i>Brain Pathology</i> , 2019, 29, 707-725.	2.1	12
691	IGF1R as druggable target mediating PI3K inhibitor resistance in a murine model of chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 534-547.	0.6	51
692	Oncogenic PI3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells. <i>Open Biology</i> , 2019, 9, 190052.	1.5	17
693	The PTEN-PI3K Axis in Cancer. <i>Biomolecules</i> , 2019, 9, 153.	1.8	178
694	PI3K pathway defects leading to immunodeficiency and immune dysregulation. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1676-1687.	1.5	104
695	Structure Overhaul Affords a Potent Purine PI3K Inhibitor with Improved Tolerability. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4370-4382.	2.9	13

#	ARTICLE	IF	CITATIONS
696	PGC-1 β cooperating with FOXA2 inhibits proliferation and migration of breast cancer cells. <i>Cancer Cell International</i> , 2019, 19, 93.	1.8	11
697	Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. <i>Molecular Autism</i> , 2019, 10, 17.	2.6	30
698	Akt-ing Up Just About Everywhere: Compartment-Specific Akt Activation and Function in Receptor Tyrosine Kinase Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 70.	1.8	97
699	Peptide P11 suppresses the growth of human thyroid carcinoma by inhibiting the PI3K/AKT/mTOR signaling pathway. <i>Molecular Biology Reports</i> , 2019, 46, 2665-2678.	1.0	6
700	A novel hydrogen sulfide-releasing donor, HA-ADT, suppresses the growth of human breast cancer cells through inhibiting the PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways. <i>Cancer Letters</i> , 2019, 455, 60-72.	3.2	58
701	<p>Trametes robiniophila Murr: a traditional Chinese medicine with potent anti-tumor effects</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1541-1549.	0.9	30
702	Determination of comprehensive in silico determinants as a strategy for identification of novel PI3K β inhibitors. <i>Structural Chemistry</i> , 2019, 30, 1761-1778.	1.0	4
703	The relation between PI3K/AKT signalling pathway and cancer. <i>Gene</i> , 2019, 698, 120-128.	1.0	331
704	Potent Antineoplastic Effects of Combined PI3K β and MNK Inhibition in Medulloblastoma. <i>Molecular Cancer Research</i> , 2019, 17, 1305-1315.	1.5	10
705	Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3K β -selective inhibitors for treating B-cell-mediated malignancies. <i>European Journal of Medicinal Chemistry</i> , 2019, 170, 112-125.	2.6	21
706	Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways. <i>Oncology Letters</i> , 2019, 17, 2905-2914.	0.8	22
707	The mechanism of PI3K β activation at the atomic level. <i>Chemical Science</i> , 2019, 10, 3671-3680.	3.7	75
708	Melatonin-mediated regulation of autophagy: Making sense of double-edged sword in cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 17011-17022.	2.0	16
709	PABPC1L depletion inhibits proliferation and migration via blockage of AKT pathway in human colorectal cancer cells. <i>Oncology Letters</i> , 2019, 17, 3439-3445.	0.8	29
710	ANXA2 ^{Tyr23} and FLNAs ^{Ser2152} phosphorylation associate with poor prognosis in hepatic carcinoma revealed by quantitative phosphoproteomics analysis. <i>Journal of Proteomics</i> , 2019, 200, 111-122.	1.2	16
711	Functional role of SGK3 in PI3K/Pten driven liver tumor development. <i>BMC Cancer</i> , 2019, 19, 343.	1.1	17
712	Antinociceptive and anti-inflammatory effects of cryptotanshinone through PI3K/Akt signaling pathway in a rat model of neuropathic pain. <i>Chemico-Biological Interactions</i> , 2019, 305, 127-133.	1.7	43
713	Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. <i>Molecular Cancer</i> , 2019, 18, 70.	7.9	361

#	ARTICLE	IF	CITATIONS
714	Î³-Tocotrienol Suppression of the Warburg Effect Is Mediated by AMPK Activation in Human Breast Cancer Cells. <i>Nutrition and Cancer</i> , 2019, 71, 1214-1228.	0.9	12
715	Polyphenols from <i>Pennisetum glaucum</i> grains induce MAP kinase phosphorylation and cell cycle arrest in human osteosarcoma cells. <i>Journal of Functional Foods</i> , 2019, 54, 422-432.	1.6	12
716	Highly expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3Î²/catenin and mTOR/HIF1Î±/VEGF signaling. <i>International Journal of Cancer</i> , 2019, 145, 1068-1082.	2.3	108
717	mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 755.	1.8	406
718	MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 29.	1.3	21
719	Molecular Research in Chronic Thromboembolic Pulmonary Hypertension. <i>International Journal of Molecular Sciences</i> , 2019, 20, 784.	1.8	19
720	Mechanisms of PTEN loss in cancer: It's all about diversity. <i>Seminars in Cancer Biology</i> , 2019, 59, 66-79.	4.3	214
721	PIK3CA in cancer: The past 30 years. <i>Seminars in Cancer Biology</i> , 2019, 59, 36-49.	4.3	122
722	The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 667.	1.8	19
723	A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 603-606.	1.5	18
724	Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 834-844.	1.9	28
725	GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. <i>Cell Metabolism</i> , 2019, 29, 1243-1257.e10.	7.2	56
726	Medulloblastoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 11.	18.1	376
727	NLRC3 inhibits MCTÎ±-induced pulmonary hypertension in rats via attenuating PI3K activation. <i>Journal of Cellular Physiology</i> , 2019, 234, 15963-15976.	2.0	18
728	The expanding spectrum of neurological disorders of phosphoinositide metabolism. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	23
729	Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. <i>Oncologist</i> , 2019, 24, 791-797.	1.9	36
730	Wnt/Catenin, Carbohydrate Metabolism, and PI3K-Akt Signaling Pathway-Related Genes as Potential Cancer Predictors. <i>Journal of Healthcare Engineering</i> , 2019, 2019, 1-7.	1.1	2
731	Design, Synthesis and Preliminary Biological Evaluation of Benzylsulfone Coumarin Derivatives as Anti-Cancer Agents. <i>Molecules</i> , 2019, 24, 4034.	1.7	15

#	ARTICLE	IF	CITATIONS
732	Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids. <i>Molecules</i> , 2019, 24, 4097.	1.7	54
733	Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. <i>Seminars in Cancer Biology</i> , 2022, 80, 1-17.	4.3	270
734	Spa-RQ: an Image Analysis Tool to Visualise and Quantify Spatial Phenotypes Applied to Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2019, 9, 17613.	1.6	5
735	Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3K Inhibitors. <i>Molecules</i> , 2019, 24, 4299.	1.7	2
736	PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5792.	1.8	65
737	Inhibitory effects of petasin on human colon carcinoma cells mediated by inactivation of Akt/mTOR pathway. <i>Chinese Medical Journal</i> , 2019, 132, 1071-1078.	0.9	4
738	PI3K Inhibitors in Breast Cancer Therapy. <i>Current Oncology Reports</i> , 2019, 21, 110.	1.8	120
739	PI3K in cardioprotection: Cytoskeleton, late Na ⁺ current, and mechanism of arrhythmias. <i>Channels</i> , 2019, 13, 520-532.	1.5	11
740	A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus. <i>Medicine (United States)</i> , 2019, 98, e15329.	0.4	11
741	miR-140-3p Suppresses Cell Growth And Induces Apoptosis In Colorectal Cancer By Targeting PD-L1. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10275-10285.	1.0	40
742	Cancer Treatment Goes Viral: Using Viral Proteins to Induce Tumour-Specific Cell Death. <i>Cancers</i> , 2019, 11, 1975.	1.7	10
743	Inhibition of mTOR in head and neck cancer cells alters endothelial cell morphology in a paracrine fashion. <i>Molecular Carcinogenesis</i> , 2019, 58, 161-168.	1.3	5
744	Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4815-4850.	2.9	115
745	Recent advances in the discovery of small molecules targeting glioblastoma. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 8-26.	2.6	16
746	The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. <i>Nature Communications</i> , 2019, 10, 6.	5.8	159
747	Clusterin enhances AKT-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit. <i>Journal of Cellular Physiology</i> , 2019, 234, 11188-11199.	2.0	19
748	Loss of 2 Akt (Protein Kinase B) Isoforms in Hematopoietic Cells Diminished Monocyte and Macrophage Survival and Reduces Atherosclerosis in Ldl Receptor-Null Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 156-169.	1.1	12
749	Mitochondrial dynamics and metastasis. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 827-835.	2.4	60

#	ARTICLE	IF	CITATIONS
750	Overcoming Endocrine Resistance in Breast Cancer. , 2019, , 393-422.		2
751	Oenothein B inhibits human non-small cell lung cancer A549 cell proliferation by ROS-mediated PI3K/Akt/NF- κ B signaling pathway. <i>Chemico-Biological Interactions</i> , 2019, 298, 112-120.	1.7	33
752	Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route?. <i>Journal of Cellular Physiology</i> , 2019, 234, 8259-8273.	2.0	5
753	Proproliferative function of adaptor protein GRB10 in prostate carcinoma. <i>FASEB Journal</i> , 2019, 33, 3198-3211.	0.2	13
754	ITCH nuclear translocation and H1.2 polyubiquitination negatively regulate the DNA damage response. <i>Nucleic Acids Research</i> , 2019, 47, 824-842.	6.5	19
755	Targeting Cancer at the Intersection of Signaling and Epigenetics. <i>Annual Review of Cancer Biology</i> , 2019, 3, 365-384.	2.3	4
756	Novel Therapeutic Approaches and Targets for Ovarian Cancer. , 2019, , 547-574.		2
757	New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 54-58.	0.6	7
758	Akt activation: A potential strategy to ameliorate insulin resistance. <i>Diabetes Research and Clinical Practice</i> , 2019, 156, 107092.	1.1	72
759	The Exploration of Chirality for Improved Druggability within the Human Kinome. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 441-469.	2.9	27
760	ROS and Lipid Droplet accumulation induced by high glucose exposure in healthy colon and Colorectal Cancer Stem Cells. <i>Genes and Diseases</i> , 2020, 7, 620-635.	1.5	26
761	Transfer of regulatory knowledge from human to mouse for functional genomics analysis. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2020, 1863, 194431.	0.9	98
762	Pro-survival autophagy: An emerging candidate of tumor progression through maintaining hallmarks of cancer. <i>Seminars in Cancer Biology</i> , 2020, 66, 59-74.	4.3	44
763	A functional genetic screen defines the AKT-induced senescence signaling network. <i>Cell Death and Differentiation</i> , 2020, 27, 725-741.	5.0	40
764	Mechanisms of resistance to estrogen receptor modulators in ER+/HER2 ⁺ advanced breast cancer. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 559-572.	2.4	19
765	Phosphoinositides in autophagy: current roles and future insights. <i>FEBS Journal</i> , 2020, 287, 222-238.	2.2	43
766	CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR pathway. <i>Biomedicine and Pharmacotherapy</i> , 2020, 123, 109717.	2.5	41
767	A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway. <i>BMC Cancer</i> , 2020, 20, 1.	1.1	264

#	ARTICLE	IF	CITATIONS
768	Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification. <i>Histopathology</i> , 2020, 76, 112-127.	1.6	69
769	Advances in relapsed/refractory follicular lymphoma therapeutics. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e74.	0.6	1
770	Genomic Characterization of HPV-related and Gastric-type Endocervical Adenocarcinoma: Correlation With Subtype and Clinical Behavior. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 578-586.	0.9	32
771	Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 122-139.	2.9	41
772	CPSF7 regulates liver cancer growth and metastasis by facilitating WWP2-FL and targeting the WWP2/PTEN/AKT signaling pathway. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118624.	1.9	22
773	The Role of Translation Control in Tumorigenesis and Its Therapeutic Implications. <i>Annual Review of Cancer Biology</i> , 2020, 4, 437-457.	2.3	38
774	BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF- β 2/PI3K/AKT/mTOR signalling pathway. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 223-235.	2.1	20
775	Ketamine exhibits anti-gastric cancer activity via induction of apoptosis and attenuation of PI3K/Akt/mTOR. <i>Archives of Medical Science</i> , 2020, 16, 1140-1149.	0.4	13
776	Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K/AKT Signaling for the Treatment of Metastatic Osteosarcoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2528-2541.	1.9	11
777	Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress. <i>Cancers</i> , 2020, 12, 2972.	1.7	52
778	Mesencephalic Astrocyte-Derived Neurotrophic Factor, a Prognostic Factor of Cholangiocarcinoma, Affects Sorafenib Sensitivity of Cholangiocarcinoma Cells by Deteriorating ER Stress. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9169-9184.	1.0	2
779	Nanoengineered Disruption of Heat Shock Protein 90 Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 5355-5366.	0.4	9
780	Reconstruction of lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveals functional lncRNAs in skin cutaneous melanoma. <i>BMC Cancer</i> , 2020, 20, 927.	1.1	14
781	Relationship Between Fibrinogen to Albumin Ratio and Prognosis of Gastrointestinal Stromal Tumors: A Retrospective Cohort Study. <i>Cancer Management and Research</i> , 2020, Volume 12, 8643-8651.	0.9	10
782	Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9679-9688.	1.0	19
783	Structural Features that Distinguish Inactive and Active PI3K Lipid Kinases. <i>Journal of Molecular Biology</i> , 2020, 432, 5849-5859.	2.0	28
784	Vibrational spectra, Hirshfeld surface analysis, molecular docking studies of (RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide by DFT approach. <i>Heliyon</i> , 2020, 6, e04641.	1.4	16
785	The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells. <i>Scientific Reports</i> , 2020, 10, 16208.	1.6	18

#	ARTICLE	IF	CITATIONS
786	Current clinical management of elderly patients with glioma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1037-1048.	1.1	8
787	Human Papillomavirus 16 E7 Promotes EGFR/PI3K/AKT1/NRF2 Signaling Pathway Contributing to PIR/NF- κ B Activation in Oral Cancer Cells. <i>Cancers</i> , 2020, 12, 1904.	1.7	14
788	Precision Therapy for the Treatment of Primary Immunodysregulatory Diseases. <i>Immunology and Allergy Clinics of North America</i> , 2020, 40, 511-526.	0.7	12
789	Compounds from Natural Sources as Protein Kinase Inhibitors. <i>Biomolecules</i> , 2020, 10, 1546.	1.8	37
790	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 120.	2.2	60
791	A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8563.	1.8	17
792	IGF1 α PI3K-induced β physiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity. <i>Journal of Sport and Health Science</i> , 2021, 10, 637-647.	3.3	24
793	Akt1 and dCIZ1 promote cell survival from apoptotic caspase activation during regeneration and oncogenic overgrowth. <i>Nature Communications</i> , 2020, 11, 5726.	5.8	28
794	Sterol synthesis pathway inhibition as a target for cancer treatment. <i>Cancer Letters</i> , 2020, 493, 19-30.	3.2	15
795	Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing. <i>BMC Cancer</i> , 2020, 20, 690.	1.1	11
796	Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 137.	7.1	79
797	Research advances on selective phosphatidylinositol 3 kinase $\hat{\Gamma}$ (PI3K $\hat{\Gamma}$) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127457.	1.0	9
798	Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment. <i>Cancers</i> , 2020, 12, 2143.	1.7	13
799	Small Molecule NF- κ B Pathway Inhibitors in Clinic. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5164.	1.8	120
800	Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 1094.	1.6	7
801	Phosphatidylinositol 3-kinase signalling is spatially organized at endosomal compartments by microtubule-associated protein 4. <i>Nature Cell Biology</i> , 2020, 22, 1357-1370.	4.6	43
802	Targeting Autophagy in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7836.	1.8	54
804	PIK3CA mutation enrichment and quantitation from blood and tissue. <i>Scientific Reports</i> , 2020, 10, 17082.	1.6	15

#	ARTICLE	IF	CITATIONS
805	Precision oncology in urothelial cancer. <i>ESMO Open</i> , 2020, 5, e000616.	2.0	3
806	PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 1258-1267.	1.3	47
807	Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3K β Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2244-2252.	1.3	13
808	The potential role of YAP in head and neck squamous cell carcinoma. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1264-1274.	3.2	15
809	Targeting phosphatidylinositol 3 kinase- β and - δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4382-4392.	2.5	18
810	Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity. <i>Nature Communications</i> , 2020, 11, 4629.	5.8	32
811	Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. <i>Journal of Clinical Medicine</i> , 2020, 9, 2934.	1.0	57
812	Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1395-1402.	2.8	32
813	Discovery and Development of SPR519 as a Potent, Selective, and Orally Bioavailable Inhibitor of PI3K β and mTOR Kinases for the Treatment of Solid Tumors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11121-11130.	2.9	6
814	Proteomic Analysis of Human Endometrial Tissues Reveals the Roles of PI3K/AKT/mTOR Pathway and Tumor Angiogenesis Molecules in the Pathogenesis of Endometrial Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	10
815	Identification of two core genes in glioblastomas with different isocitrate dehydrogenase mutation status. <i>Molecular Biology Reports</i> , 2020, 47, 7477-7488.	1.0	2
816	Gambogic acid affects ESCC progression through regulation of PI3K/AKT/mTOR signal pathway. <i>Journal of Cancer</i> , 2020, 11, 5568-5577.	1.2	12
817	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092727.	1.4	8
818	Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. <i>Cancers</i> , 2020, 12, 3857.	1.7	8
819	KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity. <i>Cell and Bioscience</i> , 2020, 10, 139.	2.1	9
820	A structural view of PA2G4 isoforms with opposing functions in cancer. <i>Journal of Biological Chemistry</i> , 2020, 295, 16100-16112.	1.6	16
821	GDC-0349 inhibits non-small cell lung cancer cell growth. <i>Cell Death and Disease</i> , 2020, 11, 951.	2.7	16
822	SHC014748M, a novel selective inhibitor of PI3K β , demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia. <i>Neoplasia</i> , 2020, 22, 714-724.	2.3	9

#	ARTICLE	IF	CITATIONS
823	Loss of S6K1 But Not S6K2 in the Tumor Microenvironment Suppresses Tumor Growth by Attenuating Tumor Angiogenesis. <i>Translational Oncology</i> , 2020, 13, 100767.	1.7	8
824	Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials. <i>ESMO Open</i> , 2020, 5, e000653.	2.0	5
825	NLRC3 inhibits PDGF α -induced PASMCs proliferation via PI3K-mTOR pathway. <i>Journal of Cellular Physiology</i> , 2020, 235, 9557-9567.	2.0	14
826	Effects of partial fish meal replacement with two fermented soybean meals on the growth of and protein metabolism in the Chinese mitten crab (<i>Eriocheir sinensis</i>). <i>Aquaculture Reports</i> , 2020, 17, 100328.	0.7	12
827	Dynamic extracellular matrix stiffening induces a phenotypic transformation and a migratory shift in epithelial cells. <i>Integrative Biology (United Kingdom)</i> , 2020, 12, 161-174.	0.6	14
828	GDC-0941 and CXCL8 (3-72) K11R/G31P combination therapy confers enhanced efficacy against breast cancer. <i>Future Oncology</i> , 2020, 16, 911-921.	1.1	3
829	CUDCa907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7239-7253.	1.6	35
830	A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migration. <i>Science Signaling</i> , 2020, 13, .	1.6	11
831	Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities. <i>Journal of Neuro-Oncology</i> , 2020, 150, 17-26.	1.4	9
832	VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3 β signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 104.	3.5	15
833	MBOAT7-driven phosphatidylinositol remodeling promotes the progression of clear cell renal carcinoma. <i>Molecular Metabolism</i> , 2020, 34, 136-145.	3.0	18
834	Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	0.6	125
835	<p></p>Impact of the Activation Status of the Akt/mTOR Signalling Pathway on the Clinical Behaviour of Synovial Sarcoma: Retrospective Analysis of 174 Patients at a Single Institution</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1759-1769.	0.9	4
836	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4256-4292.	2.9	59
837	Deciphering novel chemotherapy and its impact on dentistry. <i>British Dental Journal</i> , 2020, 228, 415-421.	0.3	11
838	Identification of Key Genes and Pathways for Enchondromas by Bioinformatics Analysis. <i>Dose-Response</i> , 2020, 18, 155932582090753.	0.7	0
839	A direct fluorometric activity assay for lipid kinases and phosphatases. <i>Journal of Lipid Research</i> , 2020, 61, 945-952.	2.0	6
840	Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4579.	1.8	66

#	ARTICLE	IF	CITATIONS
841	Cotargeting <sc>BET</sc> proteins overcomes resistance arising from <sc>PI3K</sc>/<sc>mTOR</sc> blockade-induced protumorigenic senescence in colorectal cancer. International Journal of Cancer, 2020, 147, 2824-2837.	2.3	6
842	Osteoclast Signal Transduction During Bone Metastasis Formation. Frontiers in Cell and Developmental Biology, 2020, 8, 507.	1.8	53
843	Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2020, 39, 126.	3.5	290
844	Protein Tyrosine Phosphatases in Tumor Progression and Metastasis: Promoter or Protection?. , 0, , .		6
845	Pharmacological methods to transcriptionally modulate double-strand break DNA repair. International Review of Cell and Molecular Biology, 2020, 354, 187-213.	1.6	8
846	Unravelling the effect of the E545K mutation on PI3K \hat{K} kinase. Chemical Science, 2020, 11, 3511-3515.	3.7	17
847	Design, Synthesis, and Biological Evaluation of Imidazo[1,2- <i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 3028-3046.	2.9	50
848	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. Gastroenterology Report, 2020, 8, 11-24.	0.6	68
849	Targeting PI3K/Akt/mTOR signaling pathway by polyphenols: Implication for cancer therapy. Life Sciences, 2020, 255, 117481.	2.0	64
850	Synthesis and biological activity of new 2,4,6-trisubstituted triazines as potential phosphoinositide 3-kinase inhibitors. Journal of Chemical Research, 2020, 44, 393-402.	0.6	1
851	Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 153-168.	8.2	399
852	Monomeric Targeted Protein Degraders. Journal of Medicinal Chemistry, 2020, 63, 11330-11361.	2.9	48
853	Synthesis and biological evaluation of new antioxidant and antiproliferative chalcogenobiotin derivatives for bladder carcinoma treatment. Bioorganic and Medicinal Chemistry, 2020, 28, 115423.	1.4	1
854	Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. BMC Cancer, 2020, 20, 347.	1.1	10
855	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. International Journal of Molecular Sciences, 2020, 21, 2907.	1.8	158
856	Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency. Allergologia Et Immunopathologia, 2020, 48, 686-693.	1.0	9
857	Discovery of an Atropisomeric PI3K \hat{K} Selective Inhibitor through Optimization of the Hinge Binding Motif. ACS Medicinal Chemistry Letters, 2020, 11, 1236-1243.	1.3	9
858	Overcoming Wnt \hat{K} -catenin dependent anticancer therapy resistance in leukaemia stem cells. Nature Cell Biology, 2020, 22, 689-700.	4.6	89

#	ARTICLE	IF	CITATIONS
859	Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2078.	1.2	163
860	Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 249-270.	2.4	14
861	FOXO1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway. <i>Molecular Oncology</i> , 2021, 15, 299-316.	2.1	47
862	Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status. <i>Journal of Clinical Pathology</i> , 2021, 74, 216-222.	1.0	11
863	Deficiency of Wiskott-Aldrich syndrome protein has opposing effect on the pro-oncogenic pathway activation in nonmalignant versus malignant lymphocytes. <i>Oncogene</i> , 2021, 40, 345-354.	2.6	8
864	Valorization of Lipopeptides Biosurfactants as Anticancer Agents. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 447-455.	0.9	23
865	Oncolytic virotherapy: Challenges and solutions. <i>Current Problems in Cancer</i> , 2021, 45, 100639.	1.0	51
866	PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective. <i>Cancer Research</i> , 2021, 81, 237-247.	0.4	26
867	Identification of MSC-AS1, a novel lncRNA for the diagnosis of laryngeal cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 1107-1118.	0.8	8
868	Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol 3-kinase (PI3K): Current and Future Prospects. <i>ChemMedChem</i> , 2021, 16, 448-457.	1.6	16
869	Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 29, 115890.	1.4	12
870	Decursin inhibits the growth of HeLa cervical cancer cells through PI3K/Akt signaling. <i>Journal of Asian Natural Products Research</i> , 2021, 23, 584-595.	0.7	5
871	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103185.	2.0	41
872	mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression. <i>Genes and Development</i> , 2021, 35, 59-64.	2.7	31
873	Shikonin induces odontoblastic differentiation of dental pulp stem cells via AKT/mTOR signaling in the presence of CD44. <i>Connective Tissue Research</i> , 2021, 62, 689-697.	1.1	16
874	MEK inhibitor resistance mechanisms and recent developments in combination trials. <i>Cancer Treatment Reviews</i> , 2021, 92, 102137.	3.4	85
875	Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112913.	2.6	20
876	Fluorescent spherical mesoporous silica nanoparticles loaded with emodin: Synthesis, cellular uptake and anticancer activity. <i>Materials Science and Engineering C</i> , 2021, 119, 111619.	3.8	15

#	ARTICLE	IF	CITATIONS
877	Cancer-associated fibroblasts-derived exosomal miR-3656 promotes the development and progression of esophageal squamous cell carcinoma via the ACAP2/PI3K-AKT signaling pathway. <i>International Journal of Biological Sciences</i> , 2021, 17, 3689-3701.	2.6	31
878	Primary Immune Regulatory Disorders and Targeted Therapies. <i>Turkish Journal of Haematology</i> , 2021, 38, 1-14.	0.2	7
879	Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. , 2021, 4, 573-595.		17
880	Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?. <i>Frontiers in Immunology</i> , 2020, 11, 595818.	2.2	13
881	The role of the PIK3CA gene in the development and aging of the brain. <i>Scientific Reports</i> , 2021, 11, 291.	1.6	3
882	Hypoglycemic Effects of Licochalcone A on the Streptozotocin-Induced Diabetic Mice and Its Mechanism Study. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 2444-2456.	2.4	21
883	Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. <i>Molecular Cell</i> , 2021, 81, 708-723.e5.	4.5	51
884	Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 32, 115997.	1.4	25
885	Dual PI3K/mTOR inhibitor NVPâ€™BEZ235 decreases the proliferation of doxorubicinâ€™resistant K562 cells. <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	6
886	Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets. <i>Cancers</i> , 2021, 13, 909.	1.7	67
887	Targeting SHIP1 and SHIP2 in Cancer. <i>Cancers</i> , 2021, 13, 890.	1.7	15
889	MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	31
890	An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 745-761.	2.5	25
891	An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors. <i>Cell Reports</i> , 2021, 34, 108744.	2.9	17
892	Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2771.	1.8	9
893	Role of Reductive versus Oxidative Stress in Tumor Progression and Anticancer Drug Resistance. <i>Cells</i> , 2021, 10, 758.	1.8	25
894	SAF-248, a novel PI3KÎ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 209-219.	2.8	3
895	Warburgâ€™s Ghostâ€™ Cancerâ€™s Self-Sustaining Phenotype: The Aberrant Carbon Flux in Cholesterol-Enriched Tumor Mitochondria via Dereglated Cholesterogenesis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 626316.	1.8	6

#	ARTICLE	IF	CITATIONS
896	A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective. <i>Molecular and Cellular Biology</i> , 2021, 41, .	1.1	15
897	Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways. <i>Current Pharmaceutical Design</i> , 2021, 27, 565-574.	0.9	8
898	Disease-related mutations in PI3K ^{Î³} disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. <i>ELife</i> , 2021, 10, .	2.8	28
899	How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 605-619.	1.1	23
900	Ginsenoside Rh1 Induces MCF-7 Cell Apoptosis and Autophagic Cell Death through ROS-Mediated Akt Signaling. <i>Cancers</i> , 2021, 13, 1892.	1.7	29
901	Multiomeric Analysis of Cereblon Expression and Its Prognostic Value in Kidney Renal Clear Cell Carcinoma, Lung Adenocarcinoma, and Skin Cutaneous Melanoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 263.	1.1	3
902	Estudos In silico sobre as atividades anticancerÃgenas do Eugenol presente no Cravo Da Ãndia (<i>Syzygium aromaticum</i>). <i>Research, Society and Development</i> , 2021, 10, e27910414165.	0.0	1
903	Expression and functional characterization of INPP4B in gallbladder cancer patients and gallbladder cancer cells. <i>BMC Cancer</i> , 2021, 21, 433.	1.1	6
904	Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer. <i>Current Medicinal Chemistry</i> , 2021, 28, 1775-1795.	1.2	17
905	Chitooligosaccharides inhibit tumor progression and induce autophagy through the activation of the p53/mTOR pathway in osteosarcoma. <i>Carbohydrate Polymers</i> , 2021, 258, 117596.	5.1	33
906	SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2. <i>Npj Breast Cancer</i> , 2021, 7, 40.	2.3	9
907	Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment. <i>Biomedicines</i> , 2021, 9, 414.	1.4	12
909	Autofluorescence Imaging of Treatment Response in Neuroendocrine Tumor Organoids. <i>Cancers</i> , 2021, 13, 1873.	1.7	17
910	Interplay Between Glucose Metabolism and Chromatin Modifications in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 654337.	1.8	12
911	Projected Dose Optimization of Amino- and Hydroxypyrrrolidine Purine PI3K ^{Î³} Immunomodulators. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5137-5156.	2.9	7
912	Role of Forkhead Box O Proteins in Hepatocellular Carcinoma Biology and Progression (Review). <i>Frontiers in Oncology</i> , 2021, 11, 667730.	1.3	19
913	The Triple Health Threat of Diabetes, Obesity, and Cancerâ€”Epidemiology, Disparities, Mechanisms, and Interventions. <i>Obesity</i> , 2021, 29, 954-959.	1.5	21
914	A somatic mutation in PIK3CD unravels a novel candidate gene for lymphatic malformation. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 208.	1.2	8

#	ARTICLE	IF	CITATIONS
915	From Benign Inflammatory Dermatitis to Cutaneous Lymphoma. DNA Copy Number Imbalances in Mycosis Fungoides versus Large Plaque Parapsoriasis. <i>Medicina (Lithuania)</i> , 2021, 57, 502.	0.8	3
916	Sequence Neighborhoods Enable Reliable Prediction of Pathogenic Mutations in Cancer Genomes. <i>Cancers</i> , 2021, 13, 2366.	1.7	6
917	Somatic PIK3R1 variation as a cause of vascular malformations and overgrowth. <i>Genetics in Medicine</i> , 2021, 23, 1882-1888.	1.1	26
919	Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer. <i>Molecular Biology Reports</i> , 2021, 48, 4797-4811.	1.0	13
920	MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. <i>Cancers</i> , 2021, 13, 2380.	1.7	12
921	Cell cycle dependence on the mevalonate pathway: Role of cholesterol and non-sterol isoprenoids. <i>Biochemical Pharmacology</i> , 2022, 196, 114623.	2.0	11
922	PIK3CA somatic mutation in sinonasal teratocarcinoma. <i>Auris Nasus Larynx</i> , 2021, 48, 530-534.	0.5	7
923	WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. <i>Nature Communications</i> , 2021, 12, 3500.	5.8	28
924	A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-34.	1.9	4
925	Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. <i>Cancer Letters</i> , 2021, 507, 97-111.	3.2	7
926	Computational Modeling of Novel Phosphoinositide 3-kinase β Inhibitors Using Molecular Docking, Molecular Dynamics, and 3D-QSAR. <i>Bulletin of the Korean Chemical Society</i> , 2021, 42, 1093-1111.	1.0	8
927	Isomer Selective Comprehensive Lipidomics Analysis of Phosphoinositides in Biological Samples by Liquid Chromatography with Data Independent Acquisition Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2021, 93, 9583-9592.	3.2	27
928	Ipriflavone Suppresses Growth of Esophageal Squamous Cell Carcinoma Through Inhibiting mTOR In Vitro and In Vivo. <i>Frontiers in Oncology</i> , 2021, 11, 648809.	1.3	3
929	Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis—New insight and futuristic vision. <i>International Journal of Biological Macromolecules</i> , 2021, 180, 739-752.	3.6	39
931	Promising Anti-cancer Therapeutics From Mushrooms: Current Findings and Future Perceptions. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, 1164-1191.	0.9	4
932	CK-3, A Novel Methylsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways. <i>Frontiers in Oncology</i> , 2021, 11, 717626.	1.3	9
933	A new layer of phosphoinositide-mediated allosteric regulation uncovered for SHIP2. <i>FASEB Journal</i> , 2021, 35, e21815.	0.2	6
934	Investigational Drug Treatments for Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 652.	1.1	8

#	ARTICLE	IF	CITATIONS
936	miRNome and Functional Network Analysis of PGRMC1 Regulated miRNA Target Genes Identify Pathways and Biological Functions Associated With Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 710337.	1.3	3
937	Comparison of COVID-19 and Lung Cancer via Reactive Oxygen Species Signaling. <i>Frontiers in Oncology</i> , 2021, 11, 708263.	1.3	6
938	Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 138, 1110-1119.	0.6	30
939	Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer. <i>Cancer Discovery</i> , 2021, 11, 3158-3177.	7.7	12
940	Emerging oncogene ATAD2: Signaling cascades and therapeutic initiatives. <i>Life Sciences</i> , 2021, 276, 119322.	2.0	16
941	Cancer Genomic Profiling in Colorectal Cancer: Current Challenges in Subtyping Colorectal Cancers Based on Somatic and Germline Variants. <i>Journal of the Anus, Rectum and Colon</i> , 2021, 5, 213-228.	0.4	2
942	Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor. <i>Animals</i> , 2021, 11, 2079.	1.0	6
943	MicroRNA-449a inhibits cell proliferation and migration by regulating mutant p53 in MDA-MB-468 cells. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1020.	0.8	2
944	The Importance of Being PI3K in the RAS Signaling Network. <i>Genes</i> , 2021, 12, 1094.	1.0	28
945	LncRNA SOX2OT alleviates mesangial cell proliferation and fibrosis in diabetic nephropathy via Akt/mTOR-mediated autophagy. <i>Molecular Medicine</i> , 2021, 27, 71.	1.9	30
946	Landscape of Current Targeted Therapies for Advanced Colorectal Cancer. , 0, , .		0
947	The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review. <i>Cancers</i> , 2021, 13, 3949.	1.7	121
948	Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors. <i>Biomedicines</i> , 2021, 9, 1045.	1.4	4
949	Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells. <i>Cellular and Molecular Biology Letters</i> , 2021, 26, 39.	2.7	38
950	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-Î and Î³. <i>Frontiers in Immunology</i> , 2021, 12, 718621.	2.2	16
951	Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1029-1054.	1.1	11
952	InÂvitro reconstitution of Sgk3 activation by phosphatidylinositol 3-phosphate. <i>Journal of Biological Chemistry</i> , 2021, 297, 100919.	1.6	11
953	An alcoholic extract of <i>Thuja orientalis</i> L. leaves inhibits autophagy by specifically targeting pro-autophagy PIK3C3/VPS34 complex. <i>Scientific Reports</i> , 2021, 11, 17712.	1.6	3

#	ARTICLE	IF	CITATIONS
954	Translational Aspects of the Mammalian Target of Rapamycin Complexes in Diabetic Nephropathy. Antioxidants and Redox Signaling, 2022, 37, 802-819.	2.5	4
955	Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharmaceutica Sinica B, 2022, 12, 558-580.	5.7	181
956	TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	24
957	Dietary astaxanthin: an excellent carotenoid with multiple health benefits. Critical Reviews in Food Science and Nutrition, 2023, 63, 3019-3045.	5.4	48
958	Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3K γ -specific inhibitors for the treatment of hematologic malignancies. Bioorganic and Medicinal Chemistry, 2021, 45, 116312.	1.4	4
959	The Landscape of PIK3CA Mutations in Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 201-215.	1.0	24
961	Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. Npj Breast Cancer, 2021, 7, 118.	2.3	3
962	PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open, 2021, 6, 100230.	2.0	15
963	Molecular oncology in gynecologic cancer. , 2022, , 606-617.e3.		0
964	Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy. , 2021, 4, 596-606.		5
965	The Metabolic Mechanisms of Breast Cancer Metastasis. Frontiers in Oncology, 2020, 10, 602416.	1.3	64
966	Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SFK3 pathway in patients with multiple myeloma. Cancer Biology and Medicine, 2021, 18, 721-733.	1.4	5
967	Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications. Frontiers in Genetics, 2020, 11, 562868.	1.1	10
969	Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma. Current Cancer Research, 2017, , 313-345.	0.2	1
970	Stratifying Cancer Therapies by Molecular Interactions and Imaging. , 2017, , 315-358.		1
971	Onkologika. , 2016, , 583-619.		1
972	Onkologika. , 2017, , 597-639.		1
973	A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity. British Journal of Cancer, 2020, 123, 542-555.	2.9	22

#	ARTICLE	IF	CITATIONS
974	Combined PI3K±-mTOR Targeting of Glioma Stem Cells. <i>Scientific Reports</i> , 2020, 10, 21873.	1.6	17
975	P63 modulates the expression of the WDFY2 gene which is implicated in cancer regulation and limb development. <i>Bioscience Reports</i> , 2019, 39, .	1.1	5
976	Small molecule targeting of SHIP1 and SHIP2. <i>Biochemical Society Transactions</i> , 2020, 48, 291-300.	1.6	21
977	p110Î PI3K as a therapeutic target of solid tumours. <i>Clinical Science</i> , 2020, 134, 1377-1397.	1.8	15
978	Cardiovascular toxicity of PI3K± inhibitors. <i>Clinical Science</i> , 2020, 134, 2595-2622.	1.8	11
982	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating Î²-Catenin Signaling. <i>Molecular Cancer Research</i> , 2021, 19, 573-584.	1.5	10
983	IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex. <i>JCI Insight</i> , 2020, 5, .	2.3	20
984	Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 3264-3276.	3.9	56
985	Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. <i>Journal of Clinical Investigation</i> , 2015, 125, 2385-2398.	3.9	111
986	Human herpesvirusâ€“encoded kinase induces B cell lymphomas in vivo. <i>Journal of Clinical Investigation</i> , 2018, 128, 2519-2534.	3.9	23
987	MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling. <i>Journal of Clinical Investigation</i> , 2019, 129, 1015-1029.	3.9	63
988	The role of RICTOR amplification in targeted therapy and drug resistance. <i>Molecular Medicine</i> , 2020, 26, 20.	1.9	18
989	Drosophila Spidey/Kar Regulates Oenocyte Growth via PI3-Kinase Signaling. <i>PLoS Genetics</i> , 2016, 12, e1006154.	1.5	22
990	VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo. <i>PLoS ONE</i> , 2015, 10, e0132655.	1.1	15
991	Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas. <i>PLoS ONE</i> , 2015, 10, e0133610.	1.1	30
992	Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study. <i>PLoS ONE</i> , 2016, 11, e0162133.	1.1	17
993	AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms. <i>PLoS ONE</i> , 2017, 12, e0169585.	1.1	16
994	BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma. <i>PLoS ONE</i> , 2017, 12, e0179948.	1.1	13

#	ARTICLE	IF	CITATIONS
995	PI3K the right partner: unique interactions and signaling by p110 α . <i>Postdoc Journal</i> , 2015, 3, 71-87.	0.4	2
996	Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, R109-R130.	1.6	24
997	Inhibition of LY294002 in retinal neovascularization via down-regulation the PI3K/AKT-VEGF pathway in vivo and in vitro. <i>International Journal of Ophthalmology</i> , 2018, 11, 1284-1289.	0.5	12
998	MYSM1-AR complex-mediated repression of Akt/c-Raf/GSK-3 β signaling impedes castration-resistant prostate cancer growth. <i>Aging</i> , 2019, 11, 10644-10663.	1.4	8
999	The long non-coding RNA SNHG12 promotes gastric cancer by activating the phosphatidylinositol 3-kinase/AKT pathway. <i>Aging</i> , 2019, 11, 10902-10922.	1.4	22
1000	miR-623 suppresses cell proliferation, migration and invasion through direct inhibition of XRCC5 in breast cancer. <i>Aging</i> , 2020, 12, 10246-10258.	1.4	16
1001	MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation. <i>Genes and Cancer</i> , 2015, 6, 503-512.	0.6	28
1002	Simultaneous inhibition of Vps34 kinase would enhance PI3K γ inhibitor cytotoxicity in the B-cell malignancies. <i>Oncotarget</i> , 2016, 7, 53515-53525.	0.8	19
1003	Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. <i>Oncotarget</i> , 2016, 7, 71235-71254.	0.8	13
1004	Targeted depletion of PI3K γ induces regression of lung squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 85063-85078.	0.8	16
1005	Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?. <i>Oncotarget</i> , 2017, 8, 14173-14191.	0.8	31
1006	E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3K β silencing. <i>Oncotarget</i> , 2016, 7, 84054-84071.	0.8	10
1007	DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway. <i>Oncotarget</i> , 2017, 8, 833-845.	0.8	58
1008	Endometrial cancer cells exhibit high expression of p110 β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. <i>Oncotarget</i> , 2017, 8, 3881-3894.	0.8	15
1009	Autophagy inhibition enhances photocytotoxicity of Photosan-II in human colorectal cancer cells. <i>Oncotarget</i> , 2017, 8, 6419-6432.	0.8	34
1010	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. <i>Oncotarget</i> , 2017, 8, 23213-23227.	0.8	15
1011	Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BE2235. <i>Oncotarget</i> , 2017, 8, 38084-38098.	0.8	16
1012	Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 44295-44311.	0.8	29

#	ARTICLE	IF	CITATIONS
1013	PI3K γ inhibition causes feedback activation of PI3K δ in the ABC subtype of diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 81794-81802.	0.8	25
1014	NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction. <i>Oncotarget</i> , 2017, 8, 83052-83062.	0.8	12
1015	Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers. <i>Oncotarget</i> , 2017, 8, 81662-81678.	0.8	61
1016	Dual inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth. <i>Oncotarget</i> , 2017, 8, 98471-98481.	0.8	21
1017	PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors. <i>Oncotarget</i> , 2017, 8, 103207-103222.	0.8	18
1018	Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities. <i>Oncotarget</i> , 2017, 8, 102150-102160.	0.8	3
1019	FOXO3 induces ubiquitylation of AKT through MUL1 regulation. <i>Oncotarget</i> , 2017, 8, 110474-110489.	0.8	16
1020	Identification of cancer prognosis-associated functional modules using differential co-expression networks. <i>Oncotarget</i> , 2017, 8, 112928-112941.	0.8	11
1021	PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. <i>Oncotarget</i> , 2017, 8, 113494-113501.	0.8	34
1022	Single-walled and multi-walled carbon nanotubes induce sequence-specific epigenetic alterations in 16 HBE cells. <i>Oncotarget</i> , 2018, 9, 20351-20365.	0.8	21
1023	Functional significance of co-occurring mutations in <i>PIK3CA</i> and <i>MAP3K1</i> in breast cancer. <i>Oncotarget</i> , 2018, 9, 21444-21458.	0.8	39
1024	Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma. <i>Oncotarget</i> , 2018, 9, 30066-30078.	0.8	10
1025	Splicing regulatory factors in breast cancer hallmarks and disease progression. <i>Oncotarget</i> , 2019, 10, 6021-6037.	0.8	19
1026	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. <i>Oncotarget</i> , 2015, 6, 10399-10414.	0.8	32
1027	Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110 δ subunit of PI3 kinase. <i>Oncotarget</i> , 2015, 6, 8062-8070.	0.8	15
1028	The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. <i>Oncotarget</i> , 2015, 6, 11061-11073.	0.8	33
1029	Chorein addiction in VPS13A overexpressing rhabdomyosarcoma cells. <i>Oncotarget</i> , 2015, 6, 10309-10319.	0.8	21
1030	The 26S proteasome is a multifaceted target for anti-cancer therapies. <i>Oncotarget</i> , 2015, 6, 24733-24749.	0.8	69

#	ARTICLE	IF	CITATIONS
1031	<i>REC8</i> is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer. <i>Oncotarget</i> , 2015, 6, 39211-39224.	0.8	26
1032	Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. <i>Oncotarget</i> , 2016, 7, 7297-7306.	0.8	29
1033	Dual PI-3 kinase/mTOR inhibition impairs autophagy flux and induces cell death independent of apoptosis and necroptosis. <i>Oncotarget</i> , 2016, 7, 5157-5175.	0.8	31
1034	eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants. <i>Oncotarget</i> , 2016, 7, 10073-10089.	0.8	23
1035	Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. <i>Oncotarget</i> , 2016, 7, 13153-13166.	0.8	66
1036	Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. <i>Oncotarget</i> , 2016, 7, 17301-17313.	0.8	22
1037	Characterization of selective and potent PI3K \hat{I} inhibitor (PI3KD-IN-015) for B-Cell malignances. <i>Oncotarget</i> , 2016, 7, 32641-32651.	0.8	7
1038	FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. <i>Oncotarget</i> , 2016, 7, 52597-52612.	0.8	45
1039	Pharmacological activation of FOXO3 suppresses triple-negative breast cancer <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 0, 7, 42110-42125.	0.8	47
1040	Giant obscurins regulate the PI3K cascade in breast epithelial cells via direct binding to the PI3K/p85 regulatory subunit. <i>Oncotarget</i> , 2016, 7, 45414-45428.	0.8	14
1041	Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma. <i>Current Medicinal Chemistry</i> , 2014, 21, 3173-3187.	1.2	39
1042	Insights from Exercise-induced Cardioprotection-from Clinical Application to Basic Research. <i>Current Pharmaceutical Design</i> , 2019, 25, 3751-3761.	0.9	4
1043	Exploring Dysregulated Signaling Pathways in Cancer. <i>Current Pharmaceutical Design</i> , 2020, 26, 429-445.	0.9	18
1044	Chemosensitization of Therapy Resistant Tumors: Targeting Multiple Cell Signaling Pathways by Lupeol, A Pentacyclic Triterpene. <i>Current Pharmaceutical Design</i> , 2020, 26, 455-465.	0.9	17
1045	Kinase Inhibitors with Redox and Anti-inflammatory Activities. <i>Current Topics in Medicinal Chemistry</i> , 2015, 15, 872-885.	1.0	3
1046	The Use of Conformational Restriction in Medicinal Chemistry. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1712-1733.	1.0	26
1047	New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 19, 2156-2176.	0.9	4
1048	Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors. <i>Anticancer Research</i> , 2016, 36, 6185-6194.	0.5	17

#	ARTICLE	IF	CITATIONS
1049	CDKL3 promotes osteosarcoma progression by activating Akt/PKB. <i>Life Science Alliance</i> , 2020, 3, e202000648.	1.3	7
1050	PIK3CA and PTEN Genes Expressions in Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2841-2846.	0.5	7
1051	Tangeretin prevents prostate cancer cell proliferation and induces apoptosis via activation of Notch signalling and regulating the androgen receptor (AR) pathway and the phosphoinositide 3-kinase (PI3k)/Akt/mTOR pathways. <i>Bangladesh Journal of Pharmacology</i> , 2015, 10, 937.	0.1	9
1052	Targeting the PI3K/AKT/mTOR/NFκB Axis in Ovarian Cancer. , 2020, 2, 68-73.		12
1053	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6345.	1.4	94
1054	Embryonic liver fordin is involved in glucose glycolysis of hepatic stellate cell by regulating PI3K/Akt signaling. <i>World Journal of Gastroenterology</i> , 2016, 22, 8519.	1.4	13
1055	Identification of potential core genes and miRNAs in testicular seminoma via bioinformatics analysis. <i>Molecular Medicine Reports</i> , 2019, 20, 4013-4022.	1.1	3
1056	Ginsenoside CK induces apoptosis and suppresses proliferation and invasion of human osteosarcoma cells through the PI3K/mTOR/p70S6K1 pathway. <i>Oncology Reports</i> , 2020, 43, 886-896.	1.2	13
1057	Mechanisms of resistance in castration-resistant prostate cancer (CRPC). <i>Translational Andrology and Urology</i> , 2015, 4, 365-80.	0.6	310
1058	New drugs for the treatment of non-Hodgkin lymphomas. <i>Chinese Clinical Oncology</i> , 2015, 4, 14.	0.4	3
1059	Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells. <i>Cancer Research and Treatment</i> , 2019, 51, 451-463.	1.3	12
1060	PI3K abrogation using pan PI3K inhibitor BKM120 give rise to a weighty anti-cancer effect on AML-derived KG-1 cells by inducing apoptosis and G2/M arrest. <i>Turkish Journal of Haematology</i> , 2020, 37, 167-176.	0.2	3
1061	Role of Akt signaling in resistance to DNA-targeted therapy. <i>World Journal of Clinical Oncology</i> , 2016, 7, 352.	0.9	48
1062	The mTOR Signalling Pathway in Cancer and the Potential mTOR Inhibitory Activities of Natural Phytochemicals. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6463-6475.	0.5	38
1063	PI3K/Akt/mTOR inhibitors in breast cancer. <i>Cancer Biology and Medicine</i> , 2015, 12, 342-54.	1.4	183
1064	A lithium-doped surface inspires immunomodulatory functions for enhanced osteointegration through PI3K/AKT signaling axis regulation. <i>Biomaterials Science</i> , 2021, 9, 8202-8220.	2.6	21
1065	The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers. , 2021, , 59-133.		0
1066	INPP4B exerts a dual role in gastric cancer progression and prognosis. <i>Journal of Cancer</i> , 2021, 12, 7201-7213.	1.2	11

#	ARTICLE	IF	CITATIONS
1067	Insulin Resistance and Cancer: In Search for a Causal Link. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11137.	1.8	46
1068	Mechanism of activation and the rewired network: New drug design concepts. <i>Medicinal Research Reviews</i> , 2022, 42, 770-799.	5.0	15
1069	Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase β (PI3K β). <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1418-1444.	2.9	9
1070	RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy. <i>Biomedicines</i> , 2021, 9, 1498.	1.4	10
1071	Circular RNAs in cell cycle regulation: Mechanisms to clinical significance. <i>Cell Proliferation</i> , 2021, 54, e13143.	2.4	27
1072	The Role of Kinase Inhibitors in Cancer Therapies. <i>Biochemistry</i> , 0, , .	0.8	0
1073	3D-QSAR and molecular docking studies of 4-methyl quinazoline derivatives as PI3K β inhibitors. <i>Journal of the Indian Chemical Society</i> , 2021, 98, 100183.	1.3	3
1074	Development of anti-breast cancer PI3K inhibitors based on 7-azaindole derivatives through scaffold hopping: Design, synthesis and in vitro biological evaluation. <i>Bioorganic Chemistry</i> , 2021, 117, 105405.	2.0	8
1075	Molecular Oncology in Gynecologic Cancer. , 2013, , 623-633.		1
1076	Targeting the PI3K-mTOR Signaling Circuitry in HPV-Associated Oral Malignancies: Novel Precision Molecular Therapies. , 2015, , 153-169.		0
1077	Neue Arzneimittel 2014. , 2015, , 37-198.		3
1078	Critical Roles of the AKT Substrate Girdin in Disease Initiation and Progression. , 2015, , 233-250.		0
1079	Inositol Lipids. , 2015, , 1-4.		0
1080	A new role for an old enemy. <i>ELife</i> , 2015, 4, e06424.	2.8	0
1083	The Impact of Cancer Treatments on Aging. , 2016, , 85-119.		0
1084	Phosphoinositide 3-Kinase. , 2016, , 1-12.		0
1085	Venous malformations: PIK3CA mutations guide new treatments. <i>Oncotarget</i> , 2016, 7, 48852-48853.	0.8	1
1086	Uterine Clear Cell Carcinoma. <i>Molecular Pathology Library</i> , 2017, , 123-142.	0.1	0

#	ARTICLE	IF	CITATIONS
1087	Modulation of Akt/mTOR Pathway Signaling by Chemoprevention. , 2017, , 93-103.		0
1088	High-Throughput Crystallography and Its Applications in Drug Discovery. , 2017, , 153-179.		0
1089	The Molecular Pathology of Serous Endometrial Cancer. Molecular Pathology Library, 2017, , 87-122.	0.1	0
1090	Inositol Lipids. , 2017, , 2286-2289.		0
1095	PIK3CA-Related Overgrowth Spectrum (PROS). , 2018, , 285-296.		0
1096	Phosphoinositide 3-Kinase. , 2018, , 3961-3972.		0
1097	Onkologika. , 2018, , 645-691.		1
1098	Pregnancy and the apoptotic pathway in experimental melanoma. Melanoma Research, 2018, 28, 286-294.	0.6	2
1100	The Influence and Regulatory Mechanism of the Basic Fibroblast Growth Factor (bFGF) on the Apoptosis of Nerve Cells Surrounding Intracerebral Hemorrhage (ICH) in Rat. Biophysics, 2019, 07, 7-12.	0.2	1
1102	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
1103	The Unfolded Protein Response in Triple-Negative Breast Cancer. Cancer Drug Discovery and Development, 2019, , 133-161.	0.2	0
1107	Vascular Anomalies. , 2020, , 299-313.		0
1110	Isolation and characterization of cytotoxic withanolides from the calyx of <i>Physalis alkekengi</i> L. var <i>franchetii</i> . Bioorganic Chemistry, 2020, 96, 103614.	2.0	13
1113	Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects. CNS and Neurological Disorders - Drug Targets, 2020, 19, 165-173.	0.8	4
1114	Exploring the selective mechanism of inhibitors towards different subtypes of class I PI3K. Chemical Physics Letters, 2021, , 139174.	1.2	1
1115	Evidence of a dual mechanism of action underlying the anti-proliferative and cytotoxic effects of ammonium-alkyloxy-stilbene-based Î±7- and Î±9-nicotinic ligands on glioblastoma cells. Pharmacological Research, 2022, 175, 105959.	3.1	9
1116	Role of plant derived bioactive compounds against cancer. South African Journal of Botany, 2022, 149, 1017-1028.	1.2	17
1117	Pleiotropic activities of RKIP in cancer: Role in survival, EMT, chemo-immuno-resistance, and autophagy. , 2020, , 47-75.		1

#	ARTICLE	IF	CITATIONS
1118	<p><p>4E-BP1<sup>Thr46</sup> Phosphorylation Association with Poor Prognosis in Quantitative Phosphoproteomics of Portal Vein Tumor Thrombus Revealed that 4E-BP1Thr46 Phosphorylation is Associated with Poor Prognosis in HCC</p>. Cancer Management and Research, 2020, Volume 12, 103-115.</p>	0.9	5
1119	Integrated Molecular Profiling as an Approach to Identify PI3K Inhibitor Resistance Mechanisms. , 0, , .		0
1121	RNA Splicing: Basic Aspects Underlie Antitumor Targeting. Recent Patents on Anti-Cancer Drug Discovery, 2020, 15, 293-305.	0.8	1
1122	Autophagic Dysfunction in Neurodegeneration. Advances in Medical Diagnosis, Treatment, and Care, 2020, , 25-62.	0.1	0
1125	Tumor Cell Secretomes in Response to Anti- and Pro-Tumorigenic Agents. Onco, 2021, 1, 101-113.	0.2	4
1126	Function of selected natural antidiabetic compounds with potential against cancer via modulation of the PI3K/AKT/mTOR cascade. Biomedicine and Pharmacotherapy, 2021, 144, 112138.	2.5	13
1127	Tumor necrosis factor- α induced protein 8 (TNFAIP8/TIPE) family is differentially expressed in oral cancer and regulates tumorigenesis through Akt/mTOR/STAT3 signaling cascade. Life Sciences, 2021, 287, 120118.	2.0	9
1128	Multi-kinase targeted therapy as a promising treatment strategy for ovarian tumors expressing sfRon receptor. Genes and Cancer, 2020, 11, 106-121.	0.6	4
1130	Ras mutations in the Erk-MAPK pathway and Cancer. , 2020, , .		0
1131	PI-3 kinase p110 β : a therapeutic target in advanced prostate cancers. American Journal of Clinical and Experimental Urology, 2014, 2, 188-98.	0.4	16
1133	Depletion of astrocyte elevated gene-1 suppresses tumorigenesis through inhibition of Akt activity in bladder cancer cells. American Journal of Translational Research (discontinued), 2017, 9, 5422-5431.	0.0	3
1137	A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers. American Journal of Cancer Research, 2021, 11, 2590-2617.	1.4	3
1138	Effect of Eriodictyol on Retinoblastoma via the PI3K/Akt Pathway. Journal of Healthcare Engineering, 2021, 2021, 1-9.	1.1	11
1139	PI3K/AKT/mTOR Signaling Pathway Is Required for JCPyV Infection in Primary Astrocytes. Cells, 2021, 10, 3218.	1.8	5
1140	Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nature Reviews Clinical Oncology, 2022, 19, 114-131.	12.5	76
1141	Recent Advances in Bio-compatible Oxygen Singlet Generation and Its Tumor Treatment. Advanced Therapeutics, 2022, 5, .	1.6	11
1142	Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors. European Journal of Medicinal Chemistry, 2022, 229, 113996.	2.6	5
1143	TC2N: A Novel Vital Oncogene or Tumor Suppressor Gene In Cancers. Frontiers in Immunology, 2021, 12, 764749.	2.2	6

#	ARTICLE	IF	CITATIONS
1144	The miR-345-3p/PPP2CA signaling axis promotes proliferation and invasion of breast cancer cells. <i>Carcinogenesis</i> , 2022, 43, 150-159.	1.3	7
1145	Pathophysiological Integration of Metabolic Reprogramming in Breast Cancer. <i>Cancers</i> , 2022, 14, 322.	1.7	9
1146	The role of ral signaling and post translational modifications (PTMs) of Ras in cancer. <i>Genome Instability & Disease</i> , 2022, 3, 22-32.	0.5	2
1147	Apple polyphenol phloretin complexed with ruthenium is capable of reprogramming the breast cancer microenvironment through modulation of PI3K/Akt/mTOR/VEGF pathways. <i>Toxicology and Applied Pharmacology</i> , 2022, 434, 115822.	1.3	12
1148	Triple combination of BET plus PI3K and NF- κ B inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma. <i>Blood Advances</i> , 2022, 6, 2346-2360.	2.5	6
1150	Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 836417.	1.6	107
1151	PI3K/AKT/p53 pathway inhibits infectious spleen and kidney necrosis virus infection by regulating autophagy and immune responses. <i>Fish and Shellfish Immunology</i> , 2022, 120, 648-657.	1.6	14
1152	Designing of kinase hinge binders: A medicinal chemistry perspective. <i>Chemical Biology and Drug Design</i> , 2022, 100, 968-980.	1.5	11
1153	Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells. <i>Oncology Reports</i> , 2022, 47, .	1.2	2
1154	CTCF regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy. <i>Npj Systems Biology and Applications</i> , 2022, 8, 5.	1.4	5
1155	Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TAEL 2014-001). <i>Haematologica</i> , 2022, 107, 2295-2303.	1.7	8
1156	Recent Advances in PI3 Kinase Inhibitors: Anticancer Activities and Structure-Activity Relationships. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 2146-2165.	1.1	5
1157	Antitumor and anticancer activity of biosurfactant. , 2022, , 495-513.		1
1158	Bioinformatics Analysis of Differential Gene and MicroRNA Expression in Lung Adenocarcinoma: Genetic Effects on Patient Prognosis, as Indicated by the TCGA Database. <i>Cancer Informatics</i> , 2022, 21, 117693512210820.	0.9	1
1159	Macropinocytosis and Cancer: From Tumor Stress to Signaling Pathways. <i>Sub-Cellular Biochemistry</i> , 2022, 98, 15-40.	1.0	19
1160	Diverse Macrophages Constituted the Glioma Microenvironment and Influenced by PTEN Status. <i>Frontiers in Immunology</i> , 2022, 13, 841404.	2.2	8
1161	Targeting the PI3K/Akt signaling pathway in pancreatic β cells to enhance their survival and function: An emerging therapeutic strategy for type 1 diabetes. <i>Journal of Diabetes</i> , 2022, 14, 247-260.	0.8	25
1162	Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment. <i>Pharmaceutics</i> , 2022, 14, 515.	2.0	10

#	ARTICLE	IF	CITATIONS
1163	Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3139-3155.	5.7	13
1164	MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy. <i>Cancer Cell International</i> , 2022, 22, 110.	1.8	13
1165	Identification of a Methylation-Regulating Genes Prognostic Signature to Predict the Prognosis and Aid Immunotherapy of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 832803.	1.8	2
1166	Identification of co-expression hub genes for ferroptosis in kidney renal clear cell carcinoma based on weighted gene co-expression network analysis and The Cancer Genome Atlas clinical data. <i>Scientific Reports</i> , 2022, 12, 4821.	1.6	4
1167	Benzimidazoles Against Certain Breast Cancer Drug Targets: A Review. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 2463-2477.	1.1	3
1168	Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment Approach. <i>ChemMedChem</i> , 2022, 17, .	1.6	3
1169	PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression. <i>Cancers</i> , 2022, 14, 1652.	1.7	23
1171	Covalent Proximity Scanning of a Distal Cysteine to Target PI3K. <i>Journal of the American Chemical Society</i> , 2022, 144, 6326-6342.	6.6	27
1172	Recent applications of vinyl sulfone motif in drug design and discovery. <i>European Journal of Medicinal Chemistry</i> , 2022, 234, 114255.	2.6	35
1173	Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy. <i>Molecules</i> , 2021, 26, 7561.	1.7	3
1175	Akt Signaling Pathway Is Activated in the Minor Salivary Glands of Patients with Primary Sjögren's Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13441.	1.8	1
1176	Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma. <i>Cancer Research</i> , 2022, 82, 708-720.	0.4	16
1177	OUP accepted manuscript. <i>Journal of Radiation Research</i> , 2022, , .	0.8	3
1178	Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors. <i>Nature Communications</i> , 2022, 13, 2057.	5.8	12
1179	QSAR analysis on a large and diverse set of potent phosphoinositide 3-kinase gamma (PI3K γ) inhibitors using MLR and ANN methods. <i>Scientific Reports</i> , 2022, 12, 6090.	1.6	9
1180	Aloperine: A Potent Modulator of Crucial Biological Mechanisms in Multiple Diseases. <i>Biomedicines</i> , 2022, 10, 905.	1.4	6
1188	Anti-tumor effects of cryptotanshinone (C19H20O3) in human osteosarcoma cell lines. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112993.	2.5	5
1191	Current therapeutics and treatment options in TNBC. , 2022, , 61-94.		4

#	ARTICLE	IF	CITATIONS
1192	Phosphoinositide phosphorylation sans kinase. <i>Nature Cell Biology</i> , 2022, 24, 604-606.	4.6	0
1193	Kinase-independent synthesis of 3-phosphorylated phosphoinositides by a phosphotransferase. <i>Nature Cell Biology</i> , 2022, 24, 708-722.	4.6	18
1194	Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 859455.	1.3	2
1195	A Review: PI3K/AKT/mTOR Signaling Pathway and Its Regulated Eukaryotic Translation Initiation Factors May Be a Potential Therapeutic Target in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 817916.	1.3	9
1196	Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors. <i>Cell Death and Disease</i> , 2022, 13, 410.	2.7	4
1197	Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax. <i>Experimental Cell Research</i> , 2022, 417, 113192.	1.2	5
1198	Kinases on Double Duty: A Review of UniProtKB Annotated Bifunctionality within the Kinome. <i>Biomolecules</i> , 2022, 12, 685.	1.8	0
1199	Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer. <i>Oncogene</i> , 2022, 41, 3445-3451.	2.6	2
1200	Interplay between PI3K/AKT pathway and heart disorders. <i>Molecular Biology Reports</i> , 2022, 49, 9767-9781.	1.0	44
1201	The diagnostic importance of pathogenic variants and variant coexistence determined by NGS-based liquid biopsy approach in patients with lung adenocarcinoma. <i>Molecular and Cellular Probes</i> , 2022, 64, 101819.	0.9	1
1202	Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3K \hat{I} Inhibitors for the Treatment of B-Cell Malignancies. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8011-8028.	2.9	7
1203	Inhibition of B-cell lymphoma 2 family proteins alters optical redox ratio, mitochondrial polarization, and cell energetics independent of cell state. <i>Journal of Biomedical Optics</i> , 2022, 27, .	1.4	1
1204	Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
1205	Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015â€“2021). <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114498.	2.6	16
1206	mTORC1-Inhibition Potentiating Metabolic Block by Tyrosine Kinase Inhibitor Ponatinib in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 2766.	1.7	3
1208	Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103749.	2.0	37
1209	Pharmacological Inhibition of Endogenous Hydrogen Sulfide Attenuates Breast Cancer Progression. <i>Molecules</i> , 2022, 27, 4049.	1.7	9
1210	P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. <i>Nature Cancer</i> , 2022, 3, 837-851.	5.7	9

#	ARTICLE	IF	CITATIONS
1211	Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway. <i>Cancer Letters</i> , 2022, 543, 215783.	3.2	24
1212	Recent trends in cancer immunotherapy: Pathways and inhibitors. , 2022, , 39-50.		0
1213	mTOR Signalling Pathway: A Potential Therapeutic Target for Ocular Neurodegenerative Diseases. <i>Antioxidants</i> , 2022, 11, 1304.	2.2	8
1214	GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway. <i>Cancer Gene Therapy</i> , 0, , .	2.2	2
1215	Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	25
1216	Molecular Characterization of the Response to Conventional Chemotherapeutics in Pro-B-ALL Cell Lines in Terms of Tumor Relapse. <i>Genes</i> , 2022, 13, 1240.	1.0	0
1217	EPAC Regulates Melanoma Growth by Stimulating mTORC1 Signaling and Loss of EPAC Signaling Dependence Correlates with Melanoma Progression. <i>Molecular Cancer Research</i> , 2022, 20, 1548-1560.	1.5	3
1218	Targeting AKT-Dependent Regulation of Antioxidant Defense Sensitizes AKT-E17K Expressing Cancer Cells to Ionizing Radiation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1219	The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103757.	2.0	8
1220	LncRNA LINC00460 facilitates the proliferation and metastasis of renal cell carcinoma via PI3K/AKT signaling pathway. <i>Journal of Cancer</i> , 2022, 13, 2844-2854.	1.2	3
1221	Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer. <i>Oncogene</i> , 2022, 41, 4211-4230.	2.6	34
1222	Identification and Validation of Three Hub Genes Involved in Cell Proliferation and Prognosis of Castration-Resistant Prostate Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-27.	1.9	2
1223	The Effects of Deoxyelephantopin on the Akt/mTOR/P70S6K Signaling Pathway in MCF-7 Breast Carcinoma Cells <i>In Vitro</i> . <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 0, , 0976500X2211140.	0.2	0
1224	Radiation combined with KRAS-MEK inhibitors enhances anticancer immunity in KRAS-mutated tumor models. <i>Translational Research</i> , 2023, 252, 79-90.	2.2	8
1225	Melatonin Inhibits the Ferroptosis Pathway in Rat Bone Marrow Mesenchymal Stem Cells by Activating the PI3K/AKT/mTOR Signaling Axis to Attenuate Steroid-Induced Osteoporosis. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-22.	1.9	8
1226	Early detection of colorectal cancer based on circular DNA and common clinical detection indicators. <i>World Journal of Gastrointestinal Surgery</i> , 2022, 14, 833-848.	0.8	3
1227	Panoramic view of microRNAs in regulating cancer stem cells. <i>Essays in Biochemistry</i> , 2022, 66, 345-358.	2.1	7
1228	Immunotherapy checkpoints in ovarian cancer vasculogenic mimicry: Tumor immune microenvironments, and drugs. <i>International Immunopharmacology</i> , 2022, 111, 109116.	1.7	3

#	ARTICLE	IF	CITATIONS
1229	In vitro and in vivo toxicity assessment of the senotherapeutic Peptide 14. <i>Toxicology Reports</i> , 2022, 9, 1632-1638.	1.6	3
1230	Development of a Robust and Scalable Synthetic Route for a Potent and Selective Isoindolinone PI3K β Inhibitor. <i>Organic Process Research and Development</i> , 2022, 26, 2915-2925.	1.3	3
1231	Luteolin enhances erlotinib's cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
1232	A novel 16-gene alternative mRNA splicing signature predicts tumor relapse and indicates immune activity in stage III hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1233	A Perspective Study on the RTK, PI3K, B-Raf, CDK and the Multi-Protein Targeting in Medicinal Chemistry. <i>Chemistry and Biodiversity</i> , 2022, 19, .	1.0	2
1234	Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10854.	1.8	8
1235	Carotenoids from Marine Microalgae as Antimelanoma Agents. <i>Marine Drugs</i> , 2022, 20, 618.	2.2	4
1236	Multi-omics Uncovering Different Faces of Clear Cell Ovarian Cancer. <i>Clinical Cancer Research</i> , 0, , OF1-OF2.	3.2	1
1238	In-silico molecular modelling, MM/GBSA binding free energy and molecular dynamics simulation study of novel pyrido fused imidazo[4,5-c]quinolines as potential anti-tumor agents. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	27
1239	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33
1240	Discovery of 2-Methyl-2-(4-(2-methyl-8-(1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-naphtho[1,2-d]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor Efficacy <i>In Vitro</i> and <i>In Vivo</i> . <i>Journal of Medicinal Chemistry</i> , 2022, 65, 12781-12801.	2.9	6
1241	Design, synthesis and pharmacological evaluation of 2-aryleurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy. <i>Bioorganic Chemistry</i> , 2022, 129, 106157.	2.0	8
1242	PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells. <i>Oncology Research</i> , 2021, 29, 235-250.	0.6	15
1243	AKT Isoforms in the Immune Response in Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 349-366.	0.7	0
1244	PI3K Isoforms in B Cells. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 235-254.	0.7	0
1245	Compound C Inhibits Ovarian Cancer Progression via PI3K-AKT-mTOR-NF κ B Pathway. <i>Cancers</i> , 2022, 14, 5099.	1.7	3
1247	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
1248	Short-chain L-3-hydroxyacyl-CoA dehydrogenase: A novel vital oncogene or tumor suppressor gene in cancers. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5

#	ARTICLE	IF	CITATIONS
1249	PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative. Journal of Personalized Medicine, 2022, 12, 1793.	1.1	2
1250	Comprehensive analysis of a homeobox family gene signature in clear cell renal cell carcinoma with regard to prognosis and immune significance. Frontiers in Oncology, 0, 12, .	1.3	2
1251	Autophagy in Hematological Malignancies. Cancers, 2022, 14, 5072.	1.7	6
1252	Prevalencia de la mutaci3n de PIK3CA en c3ncer de mama en la Argentina y su asociaci3n con variables cl3nico-patol3gicas. , 2022, 26, .		0
1253	The Question of Survival or Death: What Is the Role of Autophagy in Acute Myeloid Leukemia (AML)?. International Journal of Hematology-Oncology and Stem Cell Research, 0, , .	0.3	0
1254	Based on 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3Kl± selective inhibitors. Bioorganic Chemistry, 2023, 130, 106211.	2.0	6
1255	K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer. Cancers, 2022, 14, 5322.	1.7	1
1256	The Global research of protein post-translational modifications in the cancer field: A bibliometric and visualized study. Frontiers in Oncology, 0, 12, .	1.3	0
1257	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors. Bioorganic and Medicinal Chemistry, 2022, 74, 117067.	1.4	7
1258	Ginkgo biloba endopleura: An unexplored industrial waste as a potential source of flavonoids, lipids and anti-lung cancer compounds. Industrial Crops and Products, 2022, 189, 115851.	2.5	7
1259	Application of biomaterials for glioblastoma treatment: Promises, advances, and challenges. Materials Today Communications, 2022, 33, 104562.	0.9	0
1260	Molecular hallmarks of cancer. , 2023, , 489-505.e5.		0
1261	Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway. Cellular Signalling, 2023, 101, 110498.	1.7	7
1262	Wnt/β2-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers, 2022, 14, 5468.	1.7	8
1263	Insulin-like growth factor binding protein 5: Diverse roles in cancer. Frontiers in Oncology, 0, 12, .	1.3	8
1264	Targeting the PI3K Pathway in Gynecologic Malignancies. Current Oncology Reports, 2022, 24, 1669-1676.	1.8	1
1265	The roles and mechanisms of circular <sc>RNAs</sc> related to <sc>mTOR</sc> in cancers. Journal of Clinical Laboratory Analysis, 2022, 36, .	0.9	8
1266	13-Acetoxy sarcosolide induces apoptosis in human hepatocellular carcinoma cells through mitochondrial dysfunction and suppression of the PI3K/AKT/mTOR/p70S6K signalling pathway. Pharmaceutical Biology, 2022, 60, 2276-2285.	1.3	2

#	ARTICLE	IF	CITATIONS
1267	The Role of Primary Cilia-Associated Phosphoinositide Signaling in Development. <i>Journal of Developmental Biology</i> , 2022, 10, 51.	0.9	3
1268	An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer. <i>Journal of Cellular Biochemistry</i> , 2023, 124, 188-204.	1.2	2
1269	Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	29
1270	Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degradator of Mutant PI3K $\hat{\pm}$. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 16589-16621.	2.9	23
1271	Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway. <i>Drug Development Research</i> , 2023, 84, 172-184.	1.4	4
1272	Function-oriented synthesis of Imidazo[1,2-a]pyrazine and Imidazo[1,2-b]pyridazine derivatives as potent PI3K/mTOR dual inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022, , 115030.	2.6	3
1273	Role of circular RNAs in retinoblastoma. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	6
1274	Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases. <i>Inflammopharmacology</i> , 2023, 31, 57-75.	1.9	10
1275	Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1359.	1.8	2
1276	Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211383.	1.4	3
1277	PI3K $\hat{\pm}$ AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. <i>Biomolecules</i> , 2023, 13, 93.	1.8	16
1278	RNF7 Facilitated the Tumorigenesis of Pancreatic Cancer by Activating PI3K/Akt Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-17.	1.9	1
1279	Triazole-fused pyrimidines in target-based anticancer drug discovery. <i>European Journal of Medicinal Chemistry</i> , 2023, 249, 115101.	2.6	13
1280	Role of Phosphoinositide 3-Kinase in Regulation of NOX-Derived Reactive Oxygen Species in Cancer. <i>Antioxidants</i> , 2023, 12, 67.	2.2	5
1281	Selective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity. <i>Yonsei Medical Journal</i> , 2023, 64, 139.	0.9	2
1282	Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K $\hat{\pm}$ inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2023, 38, .	2.5	3
1283	Therapeutic potentials of medicinal plants and significance of computational tools in anti-cancer drug discovery. , 2023, , 393-455.		3
1284	The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2652.	1.8	30

#	ARTICLE	IF	CITATIONS
1383	The crosstalk between miRNAs and signaling pathways in human cancers: Potential therapeutic implications. International Review of Cell and Molecular Biology, 2024, , .	1.6	0
1393	Importance of targeting various cell signaling pathways in solid cancers. International Review of Cell and Molecular Biology, 2024, , .	1.6	0